Methods for detecting microorganisms using microorganism detection protein and other applications of cell binding components
Recombinant microbial detection probes using cell binding components and bacteriophage constructs enable rapid and sensitive detection of microorganisms in samples, overcoming the limitations of traditional culturing methods by directly identifying pathogens without enrichment.
Patent Information
- Application Number
- JP2024116946
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-30
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-06
AI Technical Summary
Current methods for detecting bacteria, viruses, and other microorganisms in biological, food, and clinical samples are slow, requiring several days due to the need for traditional culturing and enrichment, which limits the ability to quickly identify contaminants and poses risks with antibiotic-resistant strains.
The use of recombinant microbial detection probes (MDPs) that include cell binding components (CBCs) and indicator moieties to rapidly detect microorganisms by binding to them, allowing for direct detection without enrichment, using bacteriophages with specific genetic constructs to produce detectable signals.
Enables rapid detection of microorganisms in under 12 hours, achieving high sensitivity and specificity, eliminating the need for traditional culturing and allowing for quick identification of pathogens in various samples.
Smart Images

Figure 2024156722000003 
Figure 2024156722000004 
Figure 2024156722000005
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Nos. 62 / 640,793, filed March 9, 2018, and 62 / 798,980, filed January 30, 2019. The disclosures of U.S. Patent Application Nos. 13 / 773,339, 14 / 625,481, 15 / 263,619, 15 / 409,258, and U.S. Provisional Patent Application Nos. 62 / 616,956, 62 / 628,616, 62 / 661,739, 62 / 640,793, and 62 / 798,980 are incorporated by reference herein in their entireties.
[0002] FIELD OF THEINVENTION The present invention relates to methods, devices and systems for detecting microorganisms of interest using recombinant and / or conjugated proteins. [Background technology]
[0003] background There is strong importance in improving the speed and sensitivity for the detection of bacteria, viruses, and other microorganisms in biological, food, water, and clinical samples. Microbial pathogens can cause substantial morbidity in humans and livestock animals, as well as huge economic losses. Microbial detection is a high priority for the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) in light of the outbreaks of life-threatening or fatal diseases caused by the ingestion of food contaminated with certain microorganisms (e.g., Staphylococcus spp., Escherichia coli, or Salmonella spp.).
[0004] Traditional microbiological tests for detecting bacteria rely on non-selective and selective enrichment cultures, followed by plating on selective media and further testing to confirm suspected colonies. Such procedures can take several days. Various rapid methods have been studied and introduced into practice to reduce the time requirements. However, to date, methods that reduce the time requirements have drawbacks. For example, techniques involving direct immunoassays or gene probes generally lack the ability to produce results on the same day, since they require an overnight enrichment step to obtain adequate sensitivity. Polymerase chain reaction (PCR) tests also involve an amplification step, and thus are capable of both very high sensitivity and selectivity; however, economically, the sample size that can be subjected to PCR testing is limited. Thin bacterial suspensions that can be subjected to PCR are cell-free, and therefore purification and / or lengthy enrichment steps are still required.
[0005] The time required for traditional biological enrichment is dictated by the growth rate of the target bacterial population of the sample, by the effect of the sample matrix, and by the sensitivity required. In practice, most sensitive methods use overnight incubation, taking approximately 24 hours overall. Due to the time required for culture, these methods can take up to 3 days, depending on the organism to be identified and the source of the sample. This lag time is generally considered to be the cause of the delay in the detection of contaminated food. or allowing water or other products to find their way into livestock or humans. Furthermore, the rise of antibiotic-resistant bacteria and biodefense concerns has made rapid identification of bacterial pathogens in water, food and clinical samples a critical priority worldwide.
[0006] Thus, there is a need for faster, simpler and more sensitive detection and identification of microorganisms, such as bacteria and other potentially pathogenic microorganisms. Summary of the Invention [Means for solving the problem]
[0007] Abstract Embodiments of the present invention include compositions, methods, devices, systems and kits for the detection of microorganisms. In certain embodiments, a cell binding component (CBC) is used to detect a microorganism of interest. The present invention can be embodied in a variety of ways.
[0008] In one aspect, the present invention includes a method for testing a sample for the presence of a microorganism of interest using a microorganism detection probe (MDP). In some embodiments, the present invention includes a method for capturing and detecting as little as one microorganism of interest in a sample. For example, in certain embodiments, the method may include incubating the sample with a plurality of MDPs that bind to the microorganism of interest, the MDPs comprising an indicator moiety and a cell binding component (CBC), under conditions such that the microorganism binds to the plurality of MDPs; separating unbound MDPs from cell-bound MDPs; and detecting the indicator moiety on the cell-bound MDPs. In further embodiments, positive detection of the indicator moiety indicates that the microorganism of interest is present in the sample. In some embodiments, the plurality of MDPs bound to the one microorganism is at least 1×10 6 In a further embodiment, the CBC is specific for gram-negative or gram-positive bacteria. The gram-negative bacteria may be Salmonella spp or E. coli O157:H7. The gram-positive bacteria may be Listeria spp or Staphylococcus spp.
[0009] In other further and / or alternative aspects, the present invention may include a method for separating excess unbound MDP from cell-bound MDP. In some embodiments, the separating step includes capturing the target microorganism on a solid support. For example, the solid support may include at least one of a multi-well plate, a filter, a bead, a lateral flow strip, a filter strip, a filter disk, and a filter paper. The method may further include washing the captured microorganism to remove excess unbound MDP. In some embodiments, the MDP-bound microorganism is fixed to a solid support for examination by fluorescence microscopy.
[0010] In other further and / or alternative aspects, the present invention utilizes the high specificity of MDPs capable of binding microorganisms to detect low levels of microorganisms. In some embodiments, the method detects as few as 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 bacteria in a sample of standard size for the food safety industry. In other embodiments, the sample is first incubated in conditions favoring growth for an enrichment period of 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, or 2 hours or less. In some embodiments, the sample is not enriched prior to incubation with the MDPs.
[0011] In another aspect, the present invention includes a recombinant microorganism detection probe (MDP) comprising a cell binding component (CBC) and an indicator moiety. In some embodiments, the CBC is specific for gram-negative or gram-positive bacteria. The CBC may be isolated from an endolysin, or a spanin, or a tail fiber or tail spike protein specific for the microorganism of interest. The spanin may be an outer membrane spanin (RZ1) or a truncated variant thereof. Some CBCs isolated from endolysins further comprise a cell binding domain (CBD) or a truncated variant thereof.
[0012] In some embodiments, the MDP is a recombinant gene product or a conjugated protein. In further embodiments, the recombinant MDP comprises a binding domain having >95% homology to the CBC of any of the following bacteriophages: Salmonella phage SPN1S, Salmonella phage 10, Salmonella phage epsilon15, Salmonella phage SEA1, Salmonella phage Spn1s, Salmonella phage P22, Listeria phage LipZ5, Listeria phage P40, Listeria phage vB_LmoM_AG20, Listeria phage P70, Listeria phage A511, Staphylococcus phage P4W, Staphylococcus phage K, Staphylococcus phage Twort, Staphylococcus phage SA97, or Escherichia coli O157:H7 phage CBA120.
[0013] In certain embodiments of recombinant MDPs, the indicator moiety may generate an intrinsic signal. In other embodiments, the indicator moiety includes an enzyme that generates a signal upon reaction with a substrate. In yet other embodiments, the indicator moiety includes a cofactor that generates a signal upon reaction with one or more additional signal generating components. For example, the indicator moiety includes at least one of a fluorophore, a fluorescent protein, a particle, and an enzyme. The enzyme may include at least one of a luciferase, a phosphatase, a peroxidase, and a glycosidase. The luciferase gene may be a naturally occurring gene (e.g., Oplophorus luciferase, firefly luciferase, Lucia luciferase, or Renilla luciferase) or it may be a genetically engineered gene.
[0014] Also disclosed herein is a method of preparing a recombinant MDP, the method comprising the steps of generating a CBC substantially identical to at least one of an endolysin gene, a spanin gene, or a tail fiber gene of a wild-type bacteriophage or a group of bacteriophages that specifically infect a target pathogenic bacterium; preparing a fusion gene between the CBC and an indicator moiety, wherein the fusion protein product is the recombinant MDP; transforming an expression vector harboring the fusion gene to synthesize the recombinant MDP; and purifying the recombinant MDP.
[0015] Further embodiments include systems and kits for detecting Listeria, Salmonella, Staphylococcus, or E. coli O157:H7 comprising recombinant MDPs. Some embodiments further comprise a substrate for reacting with the indicator moiety of the MDP. These systems or kits may include features described with respect to the bacteriophages, compositions, and methods of the invention. In yet other embodiments, the invention includes non-transitory computer readable media for use with a method or system according to the invention.
[0016] In another aspect, the method of detecting one or more microorganisms of interest in a sample includes contacting the sample with a solid support of a device, where the solid support captures the one or more microorganisms in the sample, if any, where the device includes a first compartment containing a recombinant bacteriophage having a genetic construct inserted into a bacteriophage genome, where the construct includes a promoter and an indicator gene; contacting the recombinant bacteriophage from the first compartment with the sample, where the recombinant bacteriophage infects the one or more microorganisms in the sample, thereby producing an indicator gene product, and detecting the indicator gene product.
[0017] In some embodiments, the device further comprises a second compartment comprising a substrate, and detecting the indicator gene product is by contacting the indicator gene product with the substrate. In some embodiments, the solid support is a bead. In some embodiments, the solid support comprises polyethylene (PE), polypropylene (PP), polystyrene (PS), polylactic acid (PLA), and polyvinyl chloride (PVC).
[0018] In some embodiments, the solid support comprises one or more molecules of a cell binding component (CBC), wherein the CBC recognizes the one or more microorganisms of interest in the sample. In some embodiments, the CBC is specific for gram-negative bacteria. In some embodiments, the CBC is specific for gram-positive bacteria. In some embodiments, the gram-negative bacteria is Salmonella spp or E. coli O157:H7. In some embodiments, the gram-positive bacteria is Listeria spp or Staphylococcus spp.
[0019] In some embodiments, the CBC is isolated from an endolysin or spanin or receptor binding protein (RBP) specific for the microorganism of interest. In some embodiments, the spanin is an outer membrane spanin (RZ1) or a truncated variant thereof. In some embodiments, the RBP is a tail fiber protein or a truncated variant thereof.
[0020] In some embodiments, the CBC is isolated from the endolysin.
[0021] In some embodiments, the CBC isolated from the endolysin is the cell binding domain (CBD) or a truncated variant thereof.
[0022] In some embodiments, the device further comprises a second compartment containing a substrate, and the method further comprises adding the substrate from the second compartment to the sample simultaneously with or after adding the recombinant bacteriophage.
[0023] In some embodiments, the first compartment includes a seal and contacting the recombinant bacteriophage with the sample is by breaking the seal, where breaking the seal allows the recombinant bacteriophage from the first compartment to contact the sample and infect the one or more microorganisms in the sample, thereby producing an indicator gene product.
[0024] In some embodiments, the bacteriophage is lyophilized.
[0025] In some embodiments, the device includes a third compartment that contains a growth medium.
[0026] In some embodiments, the method includes incubating the solid support having captured one or more microorganisms of interest in the growth medium for a period of time prior to adding the recombinant bacteriophage.
[0027] In some embodiments, the device includes a stop-lock for stepwise mixing of the medium, the recombinant bacteriophage, and the substrate with the sample.
[0028] In some embodiments, the solid support is dried prior to contacting the sample, hi some embodiments, the solid support is immersed in a medium prior to contacting the sample.
[0029] In some embodiments, the solid support having captured the one or more microorganisms is incubated with the growth medium in the third compartment prior to contacting with the recombinant bacteriophage.
[0030] In some embodiments, the incubation is for 0 to 2 hours. In some embodiments, the bacteriophage is contacted with the sample for 0.5 to 3 hours before detecting the indicator gene product.
[0031] In some embodiments, the indicator gene product comprises at least one of a fluorophore, a fluorescent protein, a particle, and an enzyme. In some embodiments, the enzyme comprises at least one of a luciferase, a phosphatase, a peroxidase, and a glycosidase. In some embodiments, the luciferase is an engineered luciferase. In some embodiments, the sample is a food sample, an environmental sample, a water sample, a commercial sample, or a clinical sample.
[0032] In some embodiments, the method detects as few as 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 bacteria in a sample of standard size for the food safety industry. In some embodiments, the food sample includes meat or vegetables. In some embodiments, the sample is a food sample, a water sample, a dairy food sample, an environmental sample, a commercial sample, or a clinical sample.
[0033] In some embodiments, the sample is first incubated in conditions that favor growth for an enrichment period of 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, or 2 hours or less.
[0034] In another aspect, the present disclosure provides a system for detecting a microorganism of interest in a sample, the system comprising an apparatus including a first compartment containing a recombinant bacteriophage having a genetic construct inserted into the bacteriophage genome, the construct comprising a promoter and an indicator gene, the solid support comprising a cell binding component, and a signal detection component, the signal detection component capable of detecting the indicator gene product resulting from infecting the sample with the recombinant bacteriophage. In some embodiments, the signal detection component is a portable luminometer. In certain embodiments, for example, the following are provided: (Item 1) 1. A method for capturing and detecting as few as one microorganism of interest in a sample, the method comprising: incubating the sample with a plurality of microorganism detection probes (MDPs) that bind to the microorganisms of interest, the MDPs comprising an indicator moiety and a cell binding component (CBC), under conditions such that the microorganisms bind to the plurality of MDPs; separating unbound MDP from cell-bound MDP; and detecting the indicator moiety on MDP bound to the cells, where positive detection of the indicator moiety indicates that the microorganism of interest is present in the sample; The method includes: (Item 2) The plurality of MDPs bound to the single microorganism is at least 1×10 6 The method according to item 1, (Item 3) 2. The method of claim 1, wherein the CBC is specific for gram-negative bacteria. (Item 4) 2. The method of claim 1, wherein the CBC is specific for gram-positive bacteria. (Item 5) 4. The method according to item 3, wherein the Gram-negative bacterium is Salmonella spp or E. coli O157:H7. (Item 6) The gram-positive bacteria is Listeria spp. or Staphylococcus 5. The method according to item 4, wherein the s spp. (Item 7) 2. The method according to claim 1, wherein the CBC is isolated from an endolysin or spanin or a receptor binding protein (RBP) specific for the microorganism of interest. (Item 8) 8. The method of claim 7, wherein the spanin is outer membrane spanin (RZ1) or a truncated variant thereof. (Item 9) 8. The method of claim 7, wherein the RBP is a tail fiber protein or a truncated variant thereof. (Item 10) 2. The method of claim 1, wherein the CBC is isolated from an endolysin. (Item 11) 11. The method of claim 10, wherein the CBC isolated from the endolysin is the cell binding domain (CBD) or a truncated variant thereof. (Item 12) 2. The method of claim 1, wherein the binding domain has ≥ 95% homology to the CBC of at least one of the following bacteriophages: Salmonella phage SPN1S, Salmonella phage 10, Salmonella phage epsilon15, Salmonella phage SEA1, Salmonella phage Spn1s, Salmonella phage P22, Listeria phage LipZ5, Listeria phage P40, Listeria phage vB_LmoM_AG20, Listeria phage P70, Listeria phage A511, Staphylococcus phage P4W, Staphylococcus phage K, Staphylococcus phage Twort, Staphylococcus phage SA97, or Escherichia coli O157:H7 phage CBA120. (Item 13) 2. The method according to claim 1, wherein the separating step comprises capturing the target microorganism on a solid support. (Item 14) 14. The method of claim 13, wherein the solid support comprises at least one of a multiwell plate, a filter, a bead, a lateral flow strip, a filter strip, a filter disc, and a filter paper. (Item 15) 2. The method of claim 1, further comprising washing the captured microorganisms to remove excess unbound MDP. (Item 16) 2. The method of claim 1, wherein the microorganisms bound to the MDP are fixed to a solid support for examination by fluorescence microscopy. (Item 17) 2. The method of claim 1, wherein the MDP is a recombinant or conjugated protein. (Item 18) 2. The method of claim 1, wherein the indicator moiety comprises at least one of a fluorophore, a fluorescent protein, a particle, or an enzyme. (Item 19) 20. The method of claim 18, wherein the enzyme comprises at least one of luciferase, phosphatase, peroxidase, and glycosidase. (Item 20) 20. The method according to item 19, wherein the luciferase is a genetically engineered luciferase. Law. (Item 21) 2. The method of claim 1, wherein the sample is a food sample, an environmental sample, a water sample, a commercial sample, or a clinical sample. (Item 22) 2. The method of claim 1, wherein the method detects as few as 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bacteria in a sample of standard size for the food safety industry. (Item 23) 2. The method according to claim 1, wherein the food sample comprises meat or vegetables. (Item 24) 2. The method of claim 1, wherein the sample is first incubated in conditions that favor growth for an enrichment period of 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, or 2 hours or less. (Item 25) 2. The method of claim 1, wherein the sample is not enriched prior to incubation with the plurality of MDPs. (Item 26) 2. The method of claim 1, wherein the total time to result is less than 12 hours. (Item 27) A recombinant microbial detection probe (MDP) comprising a cell binding component (CBC) and an indicator moiety. (Item 28) 28. The recombinant MDP of item 27, wherein the CBC is specific for gram-negative bacteria. (Item 29) 28. The recombinant MDP of item 27, wherein the CBC is specific for Gram-positive bacteria. (Item 30) 28. The recombinant MDP of item 27, wherein the Gram-negative bacterium is Salmonella spp or E. coli O157:H7. (Item 31) 28. The recombinant MDP according to item 27, wherein the Gram-positive bacterium is Listeria spp or Staphylococcus spp. (Item 32) 28. The recombinant MDP of item 27, wherein said CBC is isolated from an endolysin or spanin or an RBP specific for said microorganism of interest. (Item 33) 33. The recombinant MDP of item 32, wherein the spanin is outer membrane spanin (RZ1) or a truncated variant thereof. (Item 34) 33. The recombinant MDP of claim 32, wherein the RBP is a tail fiber protein or a truncated variant thereof. (Item 35) 33. The recombinant MDP of item 32, wherein the CBC is isolated from the endolysin. (Item 36) 28. The recombinant MDP of item 27, wherein the CBC isolated from the endolysin is the cell binding domain (CBD) or a truncated variant thereof. (Item 37) 28. The recombinant MDP of item 27, wherein the binding domain has ≥ 95% homology to the CBC of any of the following bacteriophages: Salmonella phage SPN1S, Salmonella phage 10, Salmonella phage epsilon15, Salmonella phage SEA1, Salmonella phage Spn1s, Salmonella phage P22, Listeria phage LipZ5, Listeria phage P40, Listeria phage vB_LmoM_AG20, Listeria phage P70, Listeria phage A511, Staphylococcus phage P4W, Staphylococcus phage K, Staphylococcus phage Twort, Staphylococcus phage SA97, or Escherichia coli O157:H7 phage CBA120. (Item 38) 28. The recombinant MDP of item 27, wherein the indicator moiety generates an intrinsic signal, or the indicator moiety comprises an enzyme that generates a signal upon reaction with a substrate, or the indicator moiety comprises a cofactor that generates a signal upon reaction with one or more additional signal generating components. (Item 39) 28. The recombinant MDP of claim 27, wherein the MDP is a recombinant gene product or a conjugated protein. (Item 40) 28. The recombinant MDP of claim 27, wherein the indicator moiety comprises at least one of a fluorophore, a fluorescent protein, a particle, and an enzyme. (Item 41) 28. The recombinant MDP of item 27, wherein the enzyme comprises at least one of a luciferase, a phosphatase, a peroxidase, and a glycosidase. (Item 42) 42. The recombinant MDP of claim 41, wherein the luciferase is a genetically engineered luciferase. (Item 43) 1. A method for preparing a recombinant MDP, the method comprising: generating a CBC that is substantially identical to at least one of an endolysin gene, a spanin gene, or a tail fiber gene of a wild-type bacteriophage or a group of bacteriophages that specifically infect a target pathogenic bacterium; preparing a fusion gene between said CBC and indicator moiety, wherein the fusion protein product is said recombinant MDP; transforming an expression vector carrying the fusion gene to synthesize the recombinant MDP; and purifying the recombinant MDP; The method includes: (Item 44) 46. A kit for detecting Listeria, Salmonella, Staphylococcus, or E. coli O157:H7, said kit comprising a recombinant MDP according to any one of items 29 to 45. (Item 45) 45. The kit of claim 44, further comprising a substrate for reacting with the indicator moiety of the MDP. (Item 46) A system for detecting Listeria, Salmonella, Staphylococcus, or E. coli O157:H7 comprising a recombinant MDP. (Item 47) A method for detecting one or more microorganisms of interest in a sample, comprising: The law is contacting the sample with a solid support of a device, wherein the solid support captures the one or more microorganisms, if any, in the sample, wherein the device has a first compartment containing a recombinant bacteriophage having a genetic construct inserted into the bacteriophage genome, wherein the construct includes a promoter and an indicator gene; A process comprising: contacting the sample with the recombinant bacteriophage from the first compartment, wherein the recombinant bacteriophage infects the one or more microorganisms in the sample, thereby producing an indicator gene product; and detecting the indicator gene product; The method includes: (Item 48) 48. The method of claim 47, wherein the device further comprises a second compartment containing a substrate, and detecting the indicator gene product is by contacting the indicator gene product with a substrate. (Item 49) 48. The method of claim 47, wherein the solid support is a bead. (Item 50) 50. The method according to any one of items 47 to 49, wherein the solid support comprises polyethylene (PE), polypropylene (PP), polystyrene (PS), polylactic acid (PLA) and polyvinyl chloride (PVC). (Item 51) 51. The method according to any of items 47 to 50, wherein the solid support comprises one or more molecules of a cell binding component (CBC), wherein the CBC recognizes the one or more microorganisms of interest in the sample. (Item 52) 52. The method of claim 51, wherein the CBC is specific for gram-negative bacteria. (Item 53) 52. The method of claim 51, wherein the CBC is specific for gram-positive bacteria. (Item 54) 53. The method according to item 52, wherein the Gram-negative bacterium is Salmonella spp or E. coli O157:H7. (Item 55) 54. The method according to item 53, wherein the Gram-positive bacterium is Listeria spp or Staphylococcus spp. (Item 56) 52. The method of claim 51, wherein the CBC is isolated from an endolysin or spanin or receptor binding protein (RBP) specific for the microorganism of interest. (Item 57) 57. The method of claim 56, wherein the spanin is outer membrane spanin (RZ1) or a truncated variant thereof. (Item 58) 57. The method of claim 56, wherein the RBP is a tail fiber protein or a truncated variant thereof. (Item 59) 52. The method of claim 51, wherein the CBC is isolated from the endolysin. (Item 60) 57. The method of claim 56, wherein the CBC isolated from the endolysin is the cell binding domain (CBD) or a truncated variant thereof. (Item 61) The device further comprises a second compartment containing a substrate, and the method further comprises: adding the substrate from the second compartment to the sample simultaneously with or after adding the recombinant bacteriophage; The method according to item 47, further comprising: (Item 62) 62. The method of any of items 47 to 61, wherein the first compartment comprises a seal, and the step of contacting the recombinant bacteriophage with the sample is by breaking the seal, wherein breaking the seal allows the recombinant bacteriophage from the first compartment to contact the sample and infect the one or more microorganisms in the sample, thereby producing an indicator gene product. (Item 63) 48. The method of claim 47, wherein the bacteriophage is lyophilized. (Item 64) 48. The method of claim 47, wherein the device comprises a third compartment containing a growth medium. (Item 65) 65. The method of claim 64, wherein the method comprises incubating the solid support having captured the one or more microorganisms of interest in the growth medium for a period of time prior to adding the recombinant bacteriophage. (Item 66) 66. The method of claim 47 or 65, wherein the device comprises a stop-lock for stepwise mixing of the medium, the recombinant bacteriophage, and the substrate with the sample. (Item 67) 48. The method of claim 47, wherein the solid support is dried prior to contacting with the sample. (Item 68) 48. The method of claim 47, wherein the solid support is immersed in a medium before contacting the sample. (Item 69) 65. The method of claim 64, wherein the solid support capturing the one or more microorganisms is incubated with the growth medium in the third compartment prior to contacting with the recombinant bacteriophage. (Item 70) 70. The method according to item 69, wherein the incubation is for 0 to 2 hours. (Item 71) Item 72. The method according to any one of Items 47 to 70, wherein the bacteriophage is contacted with the sample for 0.5 to 3 hours before detecting the indicator gene product. 48. The method of claim 47, wherein the indicator gene product comprises at least one of a fluorophore, a fluorescent protein, a particle, and an enzyme. (Item 73) 48. The method of claim 47, wherein the enzyme comprises at least one of luciferase, phosphatase, peroxidase, and glycosidase. (Item 74) 74. The method of claim 73, wherein the luciferase is a genetically engineered luciferase. (Item 75) 48. The method of claim 47, wherein the sample is a food sample, an environmental sample, a water sample, a commercial sample, or a clinical sample. (Item 76) 48. The method of claim 47, wherein the method detects as few as 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bacteria in a sample of standard size for the food safety industry. (Item 77) 48. The method according to claim 47, wherein the food sample comprises meat or vegetables. (Item 78) 48. The method of claim 47, wherein the sample is a food sample, a water sample, a dairy food sample, an environmental sample, a commercial sample, or a clinical sample. (Item 79) 48. The method of claim 47, wherein the sample is first incubated in conditions that favor growth for an enrichment period of 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, or 2 hours or less. (Item 80) 1. A method for detecting one or more microorganisms of interest in a sample, the method comprising: contacting the sample with a solid support of a device, wherein the solid support captures the one or more microorganisms, if any, in the sample, wherein the device comprises a first compartment comprising an MDP according to item 1; contacting the MDP from the first compartment with the sample; and detecting the indicator gene product; The method includes: (Item 81) 1. A system for detecting a microorganism of interest in a sample, the system comprising: a first compartment comprising a recombinant bacteriophage having a genetic construct inserted into the bacteriophage genome, said construct comprising a promoter and an indicator gene; wherein the solid support comprises a first compartment comprising a cell binding component; a signal detection component, wherein said signal detection component is capable of detecting the indicator gene product resulting from infecting said sample with said recombinant bacteriophage; A system comprising an apparatus including: (Item 82) 82. The system of claim 81, wherein the signal detection component is a portable luminometer. [Brief description of the drawings]
[0035] The invention can be better understood with reference to the non-limiting drawings.
[0036] [Figure 1] FIG. 1 illustrates one embodiment of a method for detecting a bacterium of interest using MDP.
[0037] [Diagram 2] FIG. 2 shows the structures of endolysins encoded by bacteriophages specific for Gram-positive and Gram-negative bacteria.
[0038] [Diagram 3] Figure 3 shows the results of detection of L. monocytogenes cultures using a self-contained device with a swab as a solid support. Signals corresponding to the presence of the bacteria were detected by a Hygiena luminometer, a GloMax luminometer, and a GloMax 20 / 20 luminometer. Table 1 shows the results from logarithmic growth phase cultures, and Table 2 shows the results from overnight cultures.
[0039] [Figure 4]Figures 4A and 4B are plots generated from the data shown in Table 1. Figure 4A shows the measurement of signal detected using the Hygiena. Swabs were inoculated into logarithmic growth phase cells at the indicated CFU levels. Samples were immediately infected with Listeria phage cocktail for 4 hours. Substrate was added and samples were read in the Hygiena luminometer. A signal of >10 RLU is considered positive. With this method, approximately 25,000 CFU are required to generate a positive result.
[0040] FIG. 4B shows measurements of signal detected using GloMax 20 / 20 and GloMax (aka GloMax 96) luminometers. Swabs were inoculated with logarithmic growth cells at the indicated CFU levels. Samples were immediately infected with Listeria phage cocktail for 4 hours. Substrate was added and samples were read on either a GloMax 20 / 20 luminometer (1 mL sample) or a GloMax luminometer (150 μl sample). A signal / background ratio >3.0 is considered positive. With this method, approximately 5,000 CFU are required to generate a positive result.
[0041] [Diagram 5] Figure 5 shows the results of detection of Salmonella in ground turkey inoculated with Salmonella. Table 3 shows the non-inoculated control samples and Table 4 shows the inoculated turkey samples. The study was repeated with various incubation and infection times.
[0042] [Figure 6]Figures 6A and 6B are plots generated from the data in Figure 5. Figure 4A shows that Salmonella inoculated turkey samples were detected as positive at every incubation and infection time tested. The turkey samples were grown at 41°C for 24 hours after inoculation before being tested with the methods disclosed in this application. In terms of relative signal: 0 hour incubation, 2 hour infection > 1 hour incubation, 0.5 hour infection > 0 hour incubation, 0.5 hour infection. Additionally, a comparison of the RLU signals shows that the GloMax luminometer has a much higher signal than that of the Hygiena luminometer.
[0043] Figure 6B shows that detection using the GloMax 20 / 20 luminometer and the GloMax luminometer produced similar signal / background ratios for the same samples. The GloMax 20 / 20 produced a larger signal (Figure 6A), but the background was significantly higher than that of the GloMax. Thus, when determining signal / background, the two luminometers perform similarly.
[0044] [Figure 7] Figure 7 shows data for detection of Salmonella in three turkey samples (samples 21, 24, and 26) that were inoculated with Salmonella prior to assay using the self-contained device. The samples were infected for the indicated durations before signal was detected.
[0045] [Figure 8]Figures 8A-8C are plots generated from the data shown in Figure 7. Figures 8A-8C show the results of an experiment in which three inoculated ground turkey samples were enriched for 24 hours and swab samples were taken and assayed. Samples 24 (Figure 8B) and 26 (Figure 8C) showed no signal in the Hygiena portable luminometer for samples that had phage infection for 30 minutes, but did show a signal for samples that had infection for 2 hours. The GloMax 20 / 20 and GloMax luminometers produced relatively low signals.
[0046] [Figure 9] Figures 9A-9C are plots generated from the data shown in Figure 7. The plots show that both the GloMax 20 / 20 and GloMax were able to detect samples 21 (Figure 9A) and 26 (Figure 9B) as positive at 30 minutes of infection (signal / background ratio >3.0 is positive), but sample 24 (Figure 9C) required 2 hours of infection to show a positive result. The results from the GloMax 20 / 20 luminometer and the GloMax luminometer were similar.
[0047] [Figure 10] FIG. 10 shows data for detection of L. monocytogenes environmental sponge samples that were surface inoculated and enriched over a 24 hour period.
[0048] [Figure 11] Figure 11 shows the detection of microorganisms in Salmonella inoculated turkey samples using the above device. Signals were measured using three different luminometers: GloMax, 3M, and Hygiena.
[0049] [Figure 12]Figures 12A and 12B show diagrams of one embodiment of a self-contained device system for detecting microorganisms, with a swab (Figure 12A) or a bead coated with cell binding component (CBC) molecules (Figure 12B) inserted into a container containing three compartments. Each compartment is separated by a snap action seal. The first compartment contains the phage, the second compartment contains the substrate, and the third compartment contains the medium. Panel A in all figures shows the solid support being a swab.
[0050] [Figure 13] Figures 13A and 13B show diagrams of one embodiment of a self-contained device system for detecting microorganisms, with a swab (Figure 13A) or a bead coated with cell binding component (CBC) molecules (Figure 13B) inserted into a container containing three compartments. Each compartment is separated by a snap action seal. The first compartment contains the phage, the second compartment contains the medium, and the third compartment contains the substrate. After incubation with the phage and the medium, the seals separating the second and third compartments can be broken.
[0051] [Figure 14] Figures 14A and 14B show diagrams of one embodiment of a self-contained device system for detecting microorganisms, with a swab (Figure 14A) or a bead coated with cell binding component (CBC) molecules (Figure 14B) inserted into a container containing three compartments. Each compartment is separated by a snap action seal. The first compartment contains the medium, the second compartment contains the phage, and the third compartment contains the substrate. [Figure 14-2] Figure 14.
[0052] [Figure 15]Figures 15A and 15B show diagrams of one embodiment of a self-contained device system for detecting microorganisms, with a swab (Figure 15A) or a bead coated with cell binding component (CBC) molecules (Figure 15B) inserted into a container containing three compartments. Each compartment is separated by a snap action seal. The first compartment contains the medium, the second compartment contains the phage, and the third compartment contains the substrate. The device has a stop-lock mechanism for stepwise mixing of the reagents.
[0053] [Figure 16] Figures 16A and 16B show diagrams of one embodiment of a self-contained device system for detecting microorganisms, with a swab (Figure 16A) or a bead coated with cell binding component (CBC) molecules (Figure 16B) inserted into a container containing three compartments. Each compartment is separated by a snap action seal. The first compartment contains the medium, the second compartment contains the phage, and the third compartment contains the substrate. The device has a stop-lock mechanism for stepwise mixing of the reagents.
[0054] FIG. 17 shows a flow diagram of an embodiment utilizing a self-contained device system for detecting microorganisms. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0055] Detailed Description of the Invention definition Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by those skilled in the art. Furthermore, unless otherwise required by context, singular terms shall include the plural, and plural terms shall include the singular. In general, the nomenclature used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein, and these techniques, are well known and commonly used in the art. Known methods and techniques are generally performed by conventional methods well known in the art and as described in various general and more specific references discussed throughout this specification, unless otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications as commonly accomplished in the art or as described herein. The nomenclature used in connection with laboratory procedures and techniques described herein are well known and commonly used in the art.
[0056] The following terms, unless otherwise indicated, shall be understood to have the following meanings:
[0057] As used herein, the terms "a," "an," and "the" can refer to one or more, unless otherwise noted.
[0058] Use of the term "or" is used to mean "and / or," unless expressly indicated to refer to alternatives only or the alternatives are not mutually exclusive, however, the present disclosure supports a definition that refers to alternatives only and "and / or." As used herein, "another" can mean at least a second or more.
[0059] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among samples.
[0060] The term "solid support" or "support" refers to a structure that provides a substrate and / or surface onto which a biomolecule can be attached. For example, a solid support can be an assay well (i.e., for example, a microtiter plate or a multiwell plate), or a solid support can be a filter, an array, or a location on a mobile support (e.g., a bead) or membrane (e.g., a filter plate or a lateral flow strip).
[0061] The term "indicator" or "indicator moiety" or "detectable moiety" or "detectable biomolecule" or "reporter" or "label" refers to a molecule that provides a signal that can be measured in a qualitative or quantitative assay. For example, an indicator moiety can include an enzyme that can be used to convert a substrate into a product that can be measured. An indicator moiety can be an enzyme (e.g., luciferase, HRP, or AP) that catalyzes a reaction that results in the emission of bioluminescence. Alternatively, an indicator moiety can be a radioisotope that can be quantified. Alternatively, an indicator moiety can be a fluorophore. Alternatively, other detectable molecules can be used.
[0062] As used herein, "bacteriophage" or "phage" includes one or more of the viruses of bacteria. In this disclosure, the terms "bacteriophage" and "phage" include viruses such as mycobacteriophage (e.g., for TB and paraTB), mycophage (e.g., for fungi), mycoplasma phage, and any other term that refers to a virus that can invade living bacteria, fungi, mycoplasma, protozoa, yeast, and other microscopic living organisms and use the organism to replicate itself. Here, "microscopic" means one millimeter or less in maximum dimension. Bacteriophages are viruses that have evolved in nature to use bacteria as a means to replicate themselves.
[0063] As used herein, "culture enrichment," "cultivating for enrichment," "cultured for enrichment," or "enrichment culture" refers to traditional culture (e.g., incubation in a medium favorable for microbial growth) and should not be confused with other possible uses of the term "enrichment" (e.g., enrichment by removing a liquid component of a sample and concentrating the microorganisms contained therein) or other forms of enrichment that do not involve traditional promotion of microbial growth. Enrichment cultures for short periods of time may be used in some embodiments of the methods described herein, but are not required, and if used at all, are for much shorter periods of time than traditional enrichment cultures.
[0064] As used herein, "recombinant" means a gene that is not found anywhere else. "Modified" refers to a genetic (i.e., nucleic acid) modification, usually done in a laboratory, to combine genetic material that is not native to the host. This term is used interchangeably herein with the term "modified."
[0065] As used herein, "RLU" refers to the relative units of light emitted, as measured by a luminometer (e.g., GLOMAX® 96) or similar instrument that detects light. For example, detection of the reaction between luciferase and an appropriate substrate (e.g., NANOLUC® and NANO-GLO®) is often reported in RLUs detected.
[0066] Overview The present invention takes advantage of the high specificity of cell-bound components (CBCs) capable of binding to specific microorganisms with high affinity to detect and / or quantitate the presence of specific microorganisms in a sample.
[0067] Disclosed herein are compositions, methods, kits, and systems that exhibit surprising sensitivity and speed of detection of microorganisms of interest in test samples (e.g., food samples, water samples, dairy samples, environmental samples, commercial samples, clinical samples, or other biological samples) using assays performed without enrichment culture or, in some embodiments, with minimal incubation times during which the microorganisms can potentially grow. The embodiments disclosed herein include a microorganism detection probe (MDP) that includes at least a cell binding component (CBC) and an indicator moiety. These compositions, methods, kits, and systems allow detection of microorganisms to be achieved in a shorter time frame than previously thought possible.
[0068] The compositions, methods, kits, and system embodiments of the present invention may be applied to the detection of various microorganisms (e.g., bacteria, fungi, yeast) in various environments, including, but not limited to, detection of pathogens from food samples, water samples, dairy samples, environmental samples, commercial samples, clinical samples, or other biological samples. The MDP-based detection embodiments disclosed herein may be adapted to any bacteria or other microorganism of interest (e.g., pathogenic microorganisms) for which CBC is available and which do not cross-react with other microorganisms. The methods of the present invention provide high detection sensitivity and specificity rapidly, without the need for traditional biological enrichment (e.g., culture). Thus, a variety of microorganisms may be detected using the methods of the present invention.
[0069] Embodiments of the methods and systems of the present invention may be applied to the detection and quantification of various microorganisms (e.g., bacteria, fungi, yeast) in various environments, including, but not limited to, detection of pathogens from food samples, water samples, dairy samples, environmental samples, commercial samples, clinical samples, or other biological samples. The methods of the present invention can rapidly provide high detection sensitivity and specificity without the need for traditional biological enrichment (e.g., culture), which is a surprising aspect since all available methods with the desired sensitivity and specificity require culture.
[0070] Also disclosed herein are systems and methods that use devices to detect microorganisms in a test sample (e.g., food samples, water samples, dairy product samples, environmental samples, commercial samples, clinical samples, or other biological samples). The methods use a self-contained device that includes a solid support and can be used to collect a sample. In some embodiments, the solid support is coated with a cell-binding component that binds with high affinity to the microorganism of interest in the sample. This allows more of the bacteria to bind to the solid support, increasing assay sensitivity and specificity. The device further includes a first compartment that contains a bacteriophage having a genetic construct inserted into the bacteriophage genome, where the construct includes a promoter and an indicator gene. The method includes contacting the recombinant bacteriophage from the first compartment with a sample such that the recombinant bacteriophage infects one or more microorganisms in the sample, thereby producing an indicator gene product ("indicator"), and detecting the indicator. In some aspects, the device further comprises a second compartment, the compartment comprising a specific substrate for detecting the indicator. In some embodiments, the method further comprises contacting the substrate with a sample infected with the bacteriophage, thereby detecting the indicator. In these embodiments, each compartment is separated from the immediately adjacent compartment by a snap-action seal. The snap-action seal, upon breakage, allows the contents of the compartment to exit the compartment and mix with the contents from the sample or with the contents from the other compartments. For example, a user may break the snap-action seal, such that recombinant bacteriophage from the first compartment contacts the sample on the solid support, thereby infecting the microorganism bound to the support. Upon infection of the microorganism, the indicator gene is expressed to produce an indicator protein, which can be detected by a variety of detection devices.The presence of the signal indicates the presence of a microorganism in the sample.
[0071] The embodiments of the device, composition, method, kit, and system of the present invention may be applied to the detection of various microorganisms (e.g., bacteria, fungi, yeast) in various environments, including, but not limited to, the detection of pathogens from food samples, water samples, dairy samples, environmental samples, commercial samples, clinical samples, or other biological samples. The detection embodiments disclosed herein may be adapted to any bacteria or other microorganism of interest (e.g., pathogenic microorganisms) for which CBC is available and which do not cross-react with other microorganisms. The method of the present invention provides high detection sensitivity and specificity rapidly, without the need for traditional biological enrichment (e.g., culture). This is a surprising aspect, since all available methods with the desired sensitivity and specificity require culture. Detection of microorganisms in a sample using the self-contained device, which contains the reagents required to detect the microorganism in a separate compartment until the time of detection, is convenient and efficient. The device is easy to use and does not require extensive training.
[0072] sample Each of the compositions, methods, kits, and system embodiments of the present invention allows for rapid detection and / or quantification of microorganisms in a sample. For example, the methods according to the present invention can be performed in a short period of time with good results.
[0073] In certain embodiments, cell-binding components (CBCs) are used to detect the microorganism of interest. Microorganisms that can be detected by the compositions, methods, kits, and systems of the present invention include pathogens of commercial, medical, or veterinary concern. Such pathogens include gram-negative bacteria, gram-positive bacteria, mycoplasma, fungi, protozoa, and yeast. Any microorganism for which a cell-binding component (CBC) specific to a particular microorganism has been identified can be detected by the method of the present invention. Those skilled in the art will recognize that there are no limitations to the application of the method of the present invention other than the availability of the required specific cell-binding component / microorganism pair.
[0074] Bacterial cells detectable by the present invention include, but are not limited to, bacterial cells that are food-borne or water-borne pathogens. Bacterial cells detectable by the present invention include, but are not limited to, all species of Salmonella, all species of Escherichia coli, including but not limited to E. coli O157:H7 (and other Shiga toxin- and enterotoxin-producing strains of E. coli), all species of Listeria (including but not limited to L. monocytogenes), and all species of Campylobacter. Bacterial cells detectable by the present invention include, but are not limited to, bacterial cells that are pathogens of medical or veterinary importance. Such pathogens include, but are not limited to, Bacillus spp., Bordetella pertussis, Brucella spp., Campylobacter jejuni, Chlamydia pneumoniae, Clostridium perfringens, Clostridium botulinum, Enterobacter spp., Klebsiella pneumoniae, Mycoplasma pneumoniae, Salmonella typhi, Salmonella typhimurium, Salmonella enteritidis, Shigella sonnei, Yersinia spp., Vibrio spp. Staphylococcus aureus, and Streptococcus spp.
[0075] The sample may be an environmental sample, a food sample, or a water sample. Some embodiments may include a medical or veterinary sample. The sample may be a liquid, solid, or semi-solid. The sample may be a swab of a solid surface. Samples may include filters from environmental materials (e.g., water samples), or air samples or aerosol samples from cyclone collectors. Samples may be samples of beef, poultry, processed foods, milk, cheese, or other dairy products. Medical or veterinary samples include, but are not limited to, blood samples, sputum samples, cerebrospinal fluid samples, and fecal samples. In some embodiments, samples may be various types of swabs.
[0076] In some embodiments, samples may be used directly in the detection methods of the present invention without preparation, concentration, or dilution. For example, liquid samples, including but not limited to, milk and juice, may be assayed directly. In other embodiments, samples may be diluted or suspended in a solution, including but not limited to, a buffered solution or bacterial culture medium. Samples that are solid or semi-solid may be suspended in a liquid by chopping, mixing, or macerating the solid in the liquid. In some embodiments, samples should be maintained within a pH range that promotes MDP attachment to the host bacterial cells. In some embodiments, the preferred pH range may be appropriate for bacteriophage attached to bacterial cells. Samples may also be diluted with divalent and monovalent cations (Na + , Mg 2+ , and K + The composition should contain appropriate concentrations of various antioxidants, including but not limited to:
[0077] In some embodiments, the sample is maintained at a temperature that maintains the viability of any pathogen cells present in the sample. During the step in which the bacteriophage are attaching to the bacterial cells, the sample may be maintained at a temperature that promotes bacteriophage activity. Such a temperature is at least about 25° C. and not more than about 45° C. In some embodiments, the sample is maintained at about 37° C. In some embodiments, the sample is subjected to gentle mixing or shaking while the MDPs are binding or attaching.
[0078] Methods for using recombinant MDPs to detect microorganisms The assay may include a variety of suitable non-inoculated control samples, for example, a control sample containing no MDP and / or a control sample containing MDP without bacteria may be assayed as a control for background signal levels.
[0079] As noted herein, in certain embodiments, the invention may include methods that use modified or signal-tagged microbial detection probes (MDPs) to detect microorganisms. The methods of the invention may be embodied in a variety of ways.
[0080] In some aspects, the present invention includes a method for detecting a microorganism of interest. The method may use a recombinant MDP or a conjugated MDP to detect the microorganism of interest. For example, in certain embodiments, the microorganism of interest is a bacterium, and the cell-binding component (CBC) is derived from a bacteriophage that specifically recognizes the bacterium of interest. In certain embodiments, the method may include detecting the bacterium of interest in a sample by incubating the sample with multiple recombinant MDPs that can bind to the bacterium of interest. The multiple MDPs bound to one microorganism may be any number greater than 1, but preferably at least 5×10 4 , or at least 1 × 10 5 , or at least 1 × 10 6 , or at least 1 × 108 , or at least 1 × 10 9 , or at least 1 × 10 10 It is MDP.
[0081] In certain embodiments, the recombinant MDP comprises an indicator moiety. The method can include detecting the indicator moiety of the MDP, where positive detection of the indicator moiety indicates that the bacterium of interest is present in the sample.
[0082] In some embodiments, the present invention may include a method for detecting as little as one microorganism of interest in a sample, comprising incubating the sample with a plurality of MDPs that bind to the microorganism of interest (wherein the MDPs comprise an indicator moiety and a CBC) under conditions such that the microorganism binds to the plurality of MDPs; separating unbound MDPs from cell-bound MDPs; and detecting the indicator moiety on the cell-bound MDPs, where positive detection of the indicator moiety indicates that the microorganism of interest is present in the sample. The amount of MDP incubated with the sample may be 1 ng, or 10 ng, or 100 ng, or 250 ng, or 500 ng, or 1000 ng. The amount of MDP incubated with the sample may be at least 5×10 8 , or at least 5 × 10 9 , or at least 5 × 10 10 , or at least 5 × 10 11 , or at least 5 × 10 12 , or at least 5 × 10 13 It could be.
[0083] In some embodiments, the detection step requires the addition of a substrate on which the indicator enzyme acts. In other embodiments, the detection step requires the addition of an enzyme and a substrate on which the indicator cofactor acts. The selection of a particular indicator is not critical to the invention, and the indicator may either generate a detectable signal by itself or may be instrumentally detectable or detectable together with one or more additional signal generating components (e.g., an enzyme / substrate signal generating system).
[0084] In some embodiments, multiple MDPs are bound to one bacterium. The multiple MDPs bound to one microorganism can be any number greater than 1, but preferably at least 5×10 4 , or at least 1 × 10 5 , or at least 1 × 10 6 , or at least 1 × 10 8 , or at least 1 × 10 9 , or at least 1 × 10 10 It is MDP.
[0085] In certain embodiments, the assay may utilize MDPs to identify the presence of specific microorganisms. The assay may be modified to accommodate a variety of sample types or sizes and assay formats. Embodiments using recombinant MDPs of the present invention may allow for rapid detection of specific bacterial strains with total assay times of less than 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, or 12 hours, depending on the sample type or size and assay format. For example, the amount of time required may be slightly shorter or longer depending on the affinity of the MDP and / or the type of bacteria detected in the assay, the type and size of the sample being tested, the complexity of the physical / chemical environment, and the concentration of endogenous non-target contaminating bacteria.
[0086] FIG. 1 illustrates an embodiment of an assay for detecting bacteria of interest using an MDP 112 according to an embodiment of the invention. The MDP includes an indicator moiety 120 (e.g., NANOLUC®) and a CBC 121. Test sample aliquots containing known amounts of bacteria 111 are dispensed into individual wells 102 of a multi-well plate 104. Aliquots of MDP 112 are added to the individual wells 102 and incubated 202 for a period of time (e.g., 5-60 minutes at 37° C.). The aliquots of MDP 112 added to individual wells in this embodiment contain at least 1×10 9 The MDPs are bound to a single bacterium 116. In this embodiment, the MDPs bound to a single bacterium of interest are at least 1×10 6The capture of the bacteria on a solid surface and washing of the captured bacteria 203 allows for the removal of excess unbound MDP 113. Plate wells containing MDP bound to the target bacteria may be assayed 204 (e.g., luciferase assay) to measure MDP indicator activity on the plate 104. Experiments utilizing this method are described herein. In some embodiments, the test sample is not concentrated (e.g., by centrifugation) but may be directly incubated with MDP for a period of time and subsequently assayed for indicator (e.g., luciferase activity). In other embodiments, various tools (e.g., centrifugation or filters) may be used to concentrate the sample or capture microorganisms in the sample before enrichment or testing. For example, a 10 mL aliquot of the prepared sample may be extracted and centrifuged to pellet cells and large debris. The pellet may be resuspended in a smaller volume for testing. In some embodiments, the resuspended pellet of microbial cells may be enriched before testing.
[0087] In some embodiments, the present invention includes a method for detecting a bacterium of interest, comprising incubating a test sample with recombinant or conjugated MDP. In some embodiments, the test sample is incubated with a very high concentration of MDP or with an excess of MDP. Surprisingly, the high concentration of MDP is suitable for binding to the microorganism of interest.
[0088] The method of the present invention may include various other steps to increase sensitivity. For example, as discussed in more detail herein, the method may include a step for capturing and a step for washing the captured and bound bacteria to remove excess MDP and increase the signal-to-noise ratio. In some embodiments, positive detection of the indicator moiety requires that the signal-to-background ratio generated by detecting the indicator moiety is at least 2.0 or at least 2.5.
[0089] In some embodiments of the method for testing a sample, the use of a large excess of MDPs requires separation of any MDP-bound bacteria or other larger entities in the sample from the excess unbound MDPs. This can be accomplished in many different ways generally known by those skilled in the art. Microbial cells can be separated through centrifugation, size filtration, or selective immobilization. In some embodiments, size filtration is accomplished through a filter well. In other embodiments, magnetic separation can be used for selective immobilization. For example, the sample can be filtered through a 0.45 μm or 0.22 μm membrane either before or after incubation with the MDPs to capture target microorganisms (e.g., bacteria) onto a solid support. The captured microorganisms can then be washed one or more times on the solid support to ensure that only specifically bound MDPs remain. Alternatively, specific or non-specific binding mechanisms can be used to capture the microorganisms onto microbeads or another solid surface. Other formats for modifying or signaling target microorganisms and methods for washing to remove excess unbound MDPs are possible.
[0090] A variety of solid supports can be used. In certain embodiments, the solid support can include a multi-well plate, a filter, a bead, a lateral flow strip, a filter strip, a filter disk, a filter paper, or a thin film designed for culturing cells (e.g., PetriFilm by 3M). Other solid supports can also be suitable. For example, in some embodiments, the test sample microorganisms can be captured by binding to the surface of a plate, or by filtering the sample through a bacteriological filter (e.g., a 0.45 μm pore size spin filter or plate filter). In one embodiment, the microorganisms captured on the filter or plate surface are then washed one or more times to remove excess unbound MDP.
[0091] Alternatively, in some embodiments, the capturing step may be based on other features of the microorganism of interest, such as size. In embodiments utilizing size-based capture, the solid support may be a spin column filter. In some embodiments, the solid support comprises a 96-well filter plate. Alternatively, the solid support for capturing may be an array, or a location on a mobile support, such as a bead.
[0092] In some embodiments, the sample may be enriched prior to testing by incubating in conditions that promote growth. In such embodiments, the enrichment period may be up to 1, 2, 3, 4, 5, 6, 7, or 8 hours or longer, depending on the sample type and size.
[0093] In other embodiments, the sample may be enriched after capture of bacteria on a solid support. In such embodiments, the enrichment period may be up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours or longer, depending on the sample type and size.
[0094] Thus, in some embodiments, the MDP comprises a detectable indicator moiety, and binding to a pathogenic cell (e.g., a bacterium) can be detected by an amplified signal generated via the indicator moiety. Thus, the method can include detecting the indicator moiety of the MDP, where detection of the indicator indicates that the bacterium of interest is present in the sample.
[0095] In some embodiments of the method of the present invention, the microorganism can be detected without any isolation or purification of the microorganism from the sample. For example, in certain embodiments, a sample containing one or more target microorganisms can be directly applied to an assay vessel (e.g., a spin column, a microtiter well, or a filter), and the assay is carried out in the assay vessel. That is, the microorganism is captured on a membrane with a pore size that is too small to allow the microorganism to pass through. Various embodiments of such assays are disclosed herein.
[0096] A test sample aliquot can be dispensed directly into the wells of a multi-well plate, MDP can be added, and after a sufficient period of time for binding, the cells can be captured on a solid surface (e.g., a plate, beads, or filter substrate) so that excess unbound MDP can be removed in one or more subsequent washing steps. A substrate for the indicator moiety (e.g., a luciferase substrate for a luciferase indicator) is then added and assayed for detection of the indicator signal. Some embodiments of the above methods can be performed on a filter plate. Some embodiments of the above methods can be performed with or without concentrating the sample before binding with MDP.
[0097] For example, in many embodiments, a multi-well plate is used to perform the assay. The choice of plate (or any other container in which the detecting step can be performed) can affect the detecting step. For example, some plates can include a colored or white background that can affect the detection of light emission. Generally, white plates have higher sensitivity but also produce higher background signals. Other color plates can produce lower background signals but have slightly lower sensitivity. Furthermore, background signals can result from light leakage from one well to another adjacent well. Some plates have white wells while the rest of the plate is black, thus preventing light leakage from well to well while allowing high signals within the wells. This combination of white wells and black plates can reduce background signals. Thus, the choice of plate or other assay container can affect the sensitivity and background signal for the assay. In some embodiments, the detection of the microorganism of interest can be completed without the need to culture the sample. For example, in certain embodiments, the total time required for detection is less than 12.0 hours, less than 11.0 hours, less than 10.0 hours, less than 9.0 hours, less than 8.0 hours, less than 7.0 hours, less than 6.0 hours, less than 5.0 hours, less than 4.0 hours, less than 3.0 hours, less than 2.5 hours, less than 2.0 hours, less than 1.5 hours, less than 1.0 hour, less than 45 minutes, or less than 30 minutes. Minimizing the time to result is important in food and environmental testing for pathogens.
[0098] In contrast to assays known in the art, the method of the present invention can detect individual microorganisms. Thus, in certain embodiments, the method can detect ≦10 cells (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9 microorganisms) or ≦20 cells, or ≦30 cells, or ≦40 cells, or ≦50 cells, or ≦60 cells, or ≦70 cells, or ≦80 cells, or ≦90 cells, or ≦100 cells, or ≦200 cells, or ≦500 cells, or ≦1000 cells of the microorganism present in a sample. For example, in certain embodiments, the MDP is highly specific for S. Aureus, Listeria, Salmonella, or E. coli. In one embodiment, the MDP can distinguish S. Aureus, Listeria, Salmonella, or E. coli in the presence of more than 100 other types of bacteria. In one embodiment, the MDPs can distinguish a specific serotype within a bacterial species (e.g., E. coli O157:H7) in the presence of more than 100 other types of bacteria. In certain embodiments, the MDPs can be used to detect one bacterium of a specific type in the sample. In certain embodiments, the recombinant MDPs detect as few as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 specific bacteria in a sample.
[0099] Thus, aspects of the invention provide methods for the detection of a microorganism in a test sample via an indicator moiety. In some embodiments, when the microorganism of interest is a bacterium, the indicator moiety may be associated with an MDP. The indicator moiety may react with a substrate to emit a detectable signal or may emit an intrinsic signal (e.g., a fluorescent protein). A fluorescent protein naturally fluoresces by emitting energy as a photon when the fluorescent moiety containing an electron absorbs the photon (intrinsic fluorescence or autofluorescence). A fluorescent protein (e.g., GFP) may be expressed as a fusion protein. In some embodiments, the detection sensitivity may reveal the presence of as few as 100, 50, 20, 10, 9, 8, 7, 6, 5, 4, 3, or 2 cells of the microorganism of interest in a test sample. In some embodiments, as little as one cell of the microorganism of interest may produce a detectable signal.
[0100] The selection of a particular indicator moiety is not critical to the invention, and the indicator moiety may either generate a detectable signal by itself or may be instrumentally detectable or detectable together with one or more additional signal generating components (e.g., an enzyme / substrate signal generating system). Many MDPs can be formed by varying either the indicator moiety and / or the specific CBC of the MDP; it will be recognized by those skilled in the art that the selection includes considerations of the microorganism to be detected and the desired means of detection.
[0101] For example, one or more signal generating components can be reacted with an indicator moiety to generate a detectable signal. In some embodiments, the indicator can be a bioluminescent compound. When the indicator moiety is an enzyme, the amplification of the detectable signal is obtained by reacting the enzyme with one or more substrates, or an additional enzyme and substrate, to generate a detectable reaction product. In an alternative signal generating system, the indicator can be a fluorescent compound, where enzymatic manipulation of the indicator is not required to generate the detectable signal. For example, fluorescent molecules, including fluorescein and rhodamine and their derivatives and analogs, are suitable for use as indicators in such systems. In yet another alternative embodiment, the indicator moiety can be a cofactor, and the amplification of the detectable signal is obtained by reacting the cofactor with the enzyme and one or more substrates, or an additional enzyme and substrate, to generate a detectable reaction product. In some embodiments, the detectable signal is chromogenic.
[0102] The detectable indicator moiety is an important feature of MDPs, which can be detected directly or indirectly. The indicator moiety provides a detectable signal by which the binding reaction is monitored and provides a qualitative and / or quantitative measurement. The relative amount and location of the signal generated by the modified or signal-tagged microorganism can serve to indicate the presence and / or amount of the microorganism. The indicator moiety can also be used to select and isolate modified or signal-tagged microorganisms by flow sorting or using magnetic separation media.
[0103] In some embodiments, the indicator moiety of the MDP may be detectable directly or after incubation with a substrate. Many different types of detectable biomolecules suitable for use as indicator moieties are known in the art, and many are commercially available. In some embodiments, the MDP includes an enzyme that serves as the indicator moiety. In some embodiments, the MDP encodes a detectable enzyme. The indicator moiety may emit light and / or be detectable by a color change. A variety of suitable enzymes are commercially available (e.g., alkaline phosphatase (AP), horseradish peroxidase (HRP), green fluorescent protein (GFP), or luciferase (Luc)). In some embodiments, these enzymes may serve as the indicator moiety. In some embodiments, firefly luciferase is the indicator moiety. In some embodiments, Oplophorus luciferase is the indicator moiety. In some embodiments, NANOLUC® is the indicator moiety. Other engineered luciferases or other enzymes that generate a detectable signal may also be suitable indicator moieties.
[0104] Thus, in some embodiments, the recombinant MDP of the above-described methods, systems or kits is a fusion protein prepared from a fusion of a portion of a wild-type bacteriophage with the sequence of an indicator protein (eg, a fluorescent protein or a luciferase protein).
[0105] Bacteriophages can infect and lyse certain bacteria. Bacteriophage genomes encode three proteins; holin, endolysin, and spanin, which together are responsible for progeny release during the phage lytic cycle. As shown in FIG. 2, endolysins (also called peptidoglycan hydrolases or murein hydrolases) bind to and lyse the cell walls of certain types of bacteria that they infect. The holin molecules disrupt the cell membrane, allowing endolysins to access the peptidoglycan in the cell wall. In Gram-positive bacteria, endolysins can contact the peptidoglycan of the cell; however, the outer membrane of Gram-negative bacteria prevents binding between endolysins and the cell wall. Generally, endolysins produced by phages specific for Gram-negative bacteria have only one catalytic domain that is responsible for lysis. In contrast, endolysins produced by phages specific for Gram-positive bacteria have two domains: an enzymatically active domain (EAD) for lysis, and a cell wall binding domain (CBD) for host recognition and high affinity binding. More specifically, the CBD of the endolysin allows the bacteriophage to recognize the bacteria with high specificity (lytic function is not required). In some embodiments, part of a wild-type bacteriophage is an endolysin sequence, specifically the cell binding domain, or a truncated portion thereof. Typically, the CBD is located at the C-terminus, but can also be found at the N-terminus or, in some cases, as a central domain.
[0106] Other types of infectious agents use cell-binding proteins for specificity as well. In some cases, the nucleic acid sequence responsible for cell binding is found within one globular EAD of an endolysin encoded by a bacteriophage specific for Gram-negative bacteria. A third type of protein, spanin, is responsible for outer membrane destruction in Gram-negative hosts. RZ1 is an outer membrane lipoprotein of the spanin complex. During the lytic cycle, the spanin complex destroys the outer membrane after the destruction of the cell wall by the endolysin. In some embodiments, the cell-binding component comprises a conserved amino acid sequence with binding functionality derived from at least one of an endolysin or a spanin.
[0107] In some cases, phages bind to specific bacteria through receptor binding proteins (RBPs). The interaction between the RBP and the bacterial cell surface determines the RBP specificity. In some phages, the RBP is located in the tail shaft, tail fiber, or tail spike. Phage tail fiber proteins play a role in both adsorption to the cell surface and polysaccharide degradation. Tail spike proteins are components of the tails of many bacteriophages. Tail spike proteins bind to the bacterial host cell surface and mediate bacterial host recognition.
[0108] It is possible that the present invention can be used to detect Gram-negative bacteria. Generally, the outer membrane of Gram-negative bacteria prevents endolysins from contacting the cell wall. However, the outer membrane can be disrupted (e.g., EDTA, detergents, etc.), so that MDPs can attach and bind to the cell wall of Gram-negative bacteria. In some embodiments, the CBC is isolated from the enzyme domain of an endolysin encoded by a bacteriophage specific for Gram-negative bacteria. In some embodiments, a conserved sequence of amino acids within the enzyme domain is responsible for cell binding and can therefore be used as a CBC. In other embodiments, a portion of a wild-type bacteriophage is an o-spanin (RZ1), tail spike, or tail fiber. In other embodiments, the CBC comprises a conserved amino acid sequence with cell binding functionality from at least one of the following proteins: endolysin, holin, spanin, tail fiber, or tail spike.
[0109] CBCs that bind to a particular type of organism may be derived from a particular infectious agent and may be used as part of an indicator to identify the presence of that organism in a test sample. Thus, the present invention proposes the use of MDPs to modify or signal microbial cells. MDPs may be recombinant or conjugated proteins or may otherwise have an indicator moiety attached. Thus, embodiments of the invention disclosed herein include modified or signal molecules having a cell binding moiety and an indicator moiety.
[0110] The lytic function of the endolysin is not required - only the cell binding function is required. Thus, in some embodiments, the indicator moiety comprises a protein fused to the CBD and emitting an intrinsic signal (e.g., a fluorescent protein or a bioluminescent protein). The indicator may emit light and / or be detectable by a color change. For example, a fluorescent protein does not require a substrate but is directly detectable with an appropriate device (e.g., a fluorescent microscope or fluorescence activated cell sorting (FACS)). In some embodiments, the indicator gene encodes an enzyme (e.g., a luciferase) that interacts with a substrate to generate a signal. In some embodiments, the indicator gene is a luciferase gene. In some embodiments, the luciferase gene is one of Oplophorus luciferase, firefly luciferase, Renilla luciferase, External Gaussia luciferase, Lucia luciferase, or an engineered luciferase, such as NANOLUC®, Rluc8.6-535, or orange nano-lantern.
[0111] Detecting the indicator may include detecting light emission. In some embodiments, a luminometer may be used to detect the reaction of the indicator (e.g., luciferase) with the substrate. Detection of RLU may be achieved with a luminometer, or other machines or devices may also be used. For example, a spectrophotometer, CCD camera, or CMOS camera may detect color changes and other light emissions. Although absolute RLU is important for detection, a high signal-to-background ratio (e.g., >2.0, >2.5, or >3.0) is also required to ensure that single cells or a small number of cells are detected.
[0112] In some embodiments, the reaction of the indicator moiety (e.g., luciferase) with the substrate may continue for 30 minutes or longer, and detection at various time points may be desirable to optimize sensitivity. For example, in an embodiment using a 96-well filter plate as the solid support and luciferase as the indicator, luminometer readings may be taken initially and at 3 minute, or 5 minute, or 10 minute, or 15 minute intervals until the reaction is complete.
[0113] Thus, in some embodiments utilizing MDPs, the invention provides a method for detecting a microorganism of interest comprising the steps of capturing at least one sample bacterium; incubating each of the bacteria with a plurality of MDPs; allowing a time for binding of CBP to a target microorganism; and detecting the indicator moiety, wherein detection of the indicator moiety indicates that the bacterium is present in the sample.
[0114] For example, in some embodiments, the test sample bacteria may be captured by binding to the surface of a plate or by filtering the sample through a bacteriological filter (e.g., a 0.45 μm pore size spin filter or plate filter). In one embodiment, the MDP is added in minimal or nominal volume to the sample captured directly on the filter. In one embodiment, the microorganisms captured on the filter or plate surface are then washed one or more times to remove excess unbound MDP.
[0115] In some embodiments, an aliquot of a test sample containing bacteria can be applied to the spin column after incubation with the recombinant MDP and one or more washes to remove any excess MDP, and the amount of indicator detected is proportional to the amount of targeted bacteria present in the sample.
[0116] The indicator (e.g., luciferase) bound to the bacteria can then be measured and quantified. In one embodiment, the solution is centrifuged through a filter and the filtrate is collected in a new container for assay (e.g., in a luminometer) after which a substrate for the indicator enzyme (e.g., luciferase substrate) is added. Alternatively, the indicator signal can be measured directly on the filter.
[0117] In one embodiment, the microorganism is a bacterium and the MDP comprises a CBC derived from a bacteriophage. In one embodiment, the indicator moiety is luciferase. Thus, in an alternative embodiment, the indicator substrate (e.g., luciferase substrate) can be incubated with a portion of the sample that remains on the filter or bound to the plate surface. Thus, in some embodiments, the solid support is a 96-well filter plate (or a regular 96-well plate) and the substrate reaction can be detected by placing the plate directly into the luminometer.
[0118] For example, in one embodiment, the invention may include a method for detecting a pathogenic bacterium of interest, comprising the steps of binding cells captured on a 96-well filter plate with a plurality of MDPs; washing away excess MDPs; and detecting the indicator (e.g., luciferase) by adding a substrate and measuring enzymatic activity directly in the 96-well plate, where detection of enzymatic activity indicates that the bacterium of interest is present in the sample.
[0119] In another embodiment, the present invention can include a method for detecting a microorganism of interest (e.g., S. Aureus), comprising binding cells in a liquid solution or suspension in a 96-well plate with a plurality of MDPs; washing away unbound MDPs from the cells with bound MDPs; and detecting the indicator (e.g., luciferase) by adding a substrate and measuring enzyme activity directly in the 96-well plate, where detection of enzyme activity indicates that the microorganism of interest (e.g., S. Aureus) is present in the sample. In some embodiments, the microorganism of interest can be captured on a solid support (e.g., on a bead or filter). This capturing can occur either during or after incubation with the MDPs. In some embodiments, the capturing is not required.
[0120] In some embodiments, the liquid solution or suspension may be a consumable test sample (e.g., vegetable wash). In some embodiments, the liquid solution or suspension may be vegetable wash fortified with concentrated LB broth, Tryptic / Tryptone Soy broth, peptone water, or nutrient broth. In some embodiments, the liquid solution or suspension may be bacteria diluted in TSB broth.
[0121] In some embodiments, target microbial cells must be intact for proper detection, i.e., the cells do not need to be viable, but the cell wall must be structurally intact, and therefore it is desirable to minimize lysis of the bacteria prior to the detection step.
[0122] In some embodiments, an initial concentration step of the sample is useful; that is, any microorganisms or other relatively large material in the sample is concentrated to remove excess liquid. However, it is possible to perform the assay without an initial concentration step. Some embodiments include an initial concentration step, which in some embodiments allows for a shorter enrichment incubation time. In other embodiments, no enrichment period is required.
[0123] Some embodiments of the test method may further include a confirmatory assay. A variety of assays are known in the art to confirm initial results, usually at a later time point. For example, the sample may be cultured (e.g., CHROMAGAR® / DYNABEADS® assay), PCR may be utilized to confirm the presence of the microbial DNA, or other confirmatory assays may be used to confirm the initial results.
[0124] Food safety assay embodiments include sample preparation steps. Some embodiments may include enrichment steps. For example, depending on sample type and size, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours of enrichment may be required. After these sample preparation steps, binding with high concentrations of recombinant MDP containing reporter or indicator can be performed in various assay formats (e.g., those shown in Figure 1).
[0125] Embodiments of the food assay may detect a single pathogenic bacterium in a sample size comparable to industry standards with a reduction in time to result of at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, depending on the sample type and size.
[0126] Thus, some embodiments of the present invention solve the need by using recombinant protein-based methods to amplify detectable signals indicating the presence of bacteria. In certain embodiments, as few as one bacterium is detected. The principles applied herein can be applied to the detection of various microorganisms. Due to the many binding sites for signal-generating MDPs on the surface of microorganisms, the indicator moiety of many MDPs may be more easily detectable than the microorganism itself. In this way, embodiments of the present invention can achieve very large signal amplification from just one cell of the microorganism of interest.
[0127] Aspects of the invention take advantage of the high specificity of binding entities capable of binding to particular microorganisms (e.g., infectious agent recognition and binding entities) as a means of detecting and / or quantifying specific microorganisms in a sample. In some embodiments, the invention takes advantage of the high specificity of cell-binding domains of infectious agents (e.g., bacteriophages).
[0128] Some embodiments of the invention disclosed and described herein utilize the discovery that one microorganism can bind to many MDPs. This principle allows the amplification of indicator signals from one or a few cells based on the specific recognition of the microbial surface by many small proteins. For example, by exposing even one bacterial cell to multiple MDPs, the indicator signal is amplified, so that one bacterium can be detected.
[0129] The unprecedented speed and sensitivity of detecting microorganisms with MDPs is an unexpected result. In some embodiments, the method of the present invention requires less than 12 hours, less than 11 hours, less than 10 hours, less than 9 hours, less than 8 hours, less than 7 hours, less than 6 hours, less than 5 hours, less than 4 hours, less than 3 hours, or less than 2 hours to detect a microorganism of interest. These are shorter time frames than previously thought. In some embodiments, the method can detect as few as 100, 50, 20, 10, 9, 8, 7, 6, 5, 4, 3, or 2 bacteria of interest. In some embodiments, as little as one cell of the bacteria is detectable. In further embodiments, the present invention includes a system (e.g., a computer system, an automated system, or a kit) that includes components for performing the methods disclosed herein and / or using the MDPs described herein.
[0130] Existing protocols for the detection of pathogenic bacteria in food are complex, expensive, slow, labor intensive, and prone to false positives. Furthermore, phage-based detection methods involve the added complexity of infectious reagents and associated regulations. Detection with recombinant MDPs specific for a given pathogen provides an effective, rapid, and simple testing alternative.
[0131] Methods for preparing recombinant MDP Some embodiments of the method for making MDPs start with the selection of wild-type bacteriophages for the sequence of the cell binding domain. Some bacteriophages are highly specific for the target bacteria. This provides an opportunity for highly specific detection.
[0132] Thus, the methods of the invention take advantage of the high specificity of binding factors associated with infectious agents that recognize and bind to specific microorganisms of interest. The ability of multiple MDP molecules to bind to a single microorganism provides a means to amplify the indicator signal, thereby allowing the detection of low levels of microorganisms (e.g., a single microorganism) present in a sample.
[0133] Bacteriophages can infect and lyse certain bacteria. Bacteriophage genomes encode three proteins; holin, endolysin, and spanin. Together, they are responsible for progeny release during the phage lytic cycle. As shown in Figure 2, endolysins (also called peptidoglycan hydrolases or murein hydrolases) bind to and lyse the cell walls of certain types of bacteria that they infect. Holin molecules disrupt the cell membrane, allowing endolysins to access the peptidoglycan in the cell wall. In Gram-positive bacteria, endolysins can contact the peptidoglycan of the cell; however, the outer membrane of Gram-negative bacteria prevents binding between endolysins and the cell wall. Generally, endolysins produced by phages specific for Gram-negative bacteria have only one catalytic domain responsible for lysis. Endolysins produced by phages specific for Gram-positive bacteria have two domains: an enzymatic activity domain (EAD) for lysis, and a cell wall binding domain (CBD) for host recognition and high affinity binding. More specifically, the CBD of the endolysin enables the bacteriophage to recognize the bacteria with high specificity (lytic function is not required). Other types of infectious agents similarly use cell-binding proteins for specificity. In some cases, the nucleic acid sequence responsible for cell binding has been found within one globular EAD of an endolysin encoded by a bacteriophage specific for Gram-negative bacteria.
[0134] A third type of protein, spanins, is responsible for outer membrane disruption in gram-negative hosts. RZ1 is an outer membrane lipoprotein of the spanin complex. During the lytic cycle, the spanin complex disrupts the outer membrane and subsequently the cell wall by the endolysins. In some embodiments, the CBC is composed of the following proteins: In another embodiment, the CBC comprises a conserved amino acid sequence with cell-binding functionality derived from an endolysin and a conserved amino acid sequence derived from at least one of a holin, a spanin, a tail spike, or a tail fiber.
[0135] In some cases, phages can bind to specific bacteria through receptor binding proteins (RBPs). The interaction between the RBP and the bacterial cell surface determines the RBP specificity. In some phages, the RBP is located in the tail shaft, tail fiber, or tail spike. Phage tail fiber proteins play a role in both cell surface adsorption and polysaccharide degradation. Tail spike proteins are components of the tails of many bacteriophages. Tail spike proteins bind to the cell surface of the bacterial host and mediate bacterial host recognition. Phage tail spike and / or tail fiber proteins play a role in both cell surface adsorption and polysaccharide degradation by attaching the phage to the bacteria.
[0136] Some phages, including CBA120, Vil, and P22, have tail spikes. Other phages, such as T4, JG04, SEA1, Saka2, and Saka4, have tail fibers. A CBC that binds to a particular type of bacteria may be derived from a particular infectious agent and may be used as part of an indicator to identify the presence of that organism in a test sample. Thus, the present invention proposes using MDPs to modify or signal enrich microbial cells by adsorption. The MDPs may be recombinant or conjugated proteins or may otherwise have an indicator moiety attached. In other embodiments, the CBC comprises a conserved amino acid sequence with cell binding functionality derived from an endolysin and a conserved amino acid sequence derived from at least one of a holin, spanin, tail spike, or tail fiber. Thus, embodiments of the invention disclosed herein include modified or signal-enriched molecules with a cell binding moiety and an indicator moiety.
[0137] Infectious agents can be highly specific for a particular type of microorganism. For example, a bacteriophage can be specific for a particular bacterial genus (e.g., Listeria). For example, the A511 bacteriophage is specific for the genus Listeria. Alternatively, a bacteriophage can be specific for a particular bacterial species (e.g., E. coli). For some types of bacteria, a bacteriophage can even recognize a particular subtype of the organism with high specificity. For example, the CBA120 bacteriophage is highly specific for E. coli O157:H7, and the φYeO3-12 bacteriophage is highly specific for Y. enterocolitica serotype O:3.
[0138] In some embodiments of the MDPs described herein, the CBC is an aspect of a recombinant or conjugated protein. Specific amino acid stretches encoded by specific segments of bacteriophage genes encoding endolysins can serve as part of highly specific cell type markers. The CBC can be derived from: T7, T4, T4-like, ViI, ViI-like, AR1, A511, A118, A006, A500, PSA, P35, P40, B025, B054, A97, phiSM101, phi3626, CBA120, SPN1S, 10, epsilon15, P22, LipZ5, P40, vB_LmoM_AG20, P70, A511, P4W, K, Twort, or SA97. MDPs also contain an indicator moiety (e.g., a fluorescent moiety, a fluorescent protein, a bioluminescent protein, or an enzyme) that enables the MDP to generate a signal. In recombinant MDPs, various types of reporters can be attached to CBP to serve as indicator moieties. In some embodiments, the MDP fusion protein contains the amino acid sequence of an enzyme (e.g., luciferase), which is only detectable upon addition of an appropriate substrate. For example, luciferase, alkaline phosphatase, and other reporter enzymes react with an appropriate substrate to provide a detectable signal. Some embodiments of recombinant MDPs contain wild-type luciferase or engineered luciferase (e.g., NANOLUC®). Other embodiments contain a fluorescent protein or another reporter protein.
[0139] A variety of infectious agents can be studied and / or serve as models for the cell-binding domain of the CBC. In alternative embodiments, bacteriophages, phages, mycobacteriophages (e.g., for TB and paraTB), mycophages (e.g., for fungi), mycoplasma phages, and any other viruses that can invade living bacteria, fungi, mycoplasma, protozoa, fungi, and other microscopic living organisms can be studied or copied to target the microorganism of interest. In one embodiment, when the microorganism of interest is a bacterium, the CBC can include a cell-binding domain derived from a bacteriophage. For example, well-studied phages of E. coli include T1, T2, T3, T4, T5, T7, and lambda; other E. coli phages available in the ATCC collection include, for example, phix174, S13, Ox6, MS2, phiV1, fd, PR772, and ZIK1. Salmonella phages include SPN1S, 10, epsilon15, SEA1, and P22. Listeria phages include LipZ5, P40, vB_LmoM_AG20, P70, and A511. Staphylococcus phages include P4W, virus K, Twort, phi11, 187, P68, and phiWMY.
[0140] Some embodiments of the method for preparing recombinant MDPs include sequencing or studying published sequences of various bacteriophages to ascertain the exact location and sequence of their cell-binding components. The sequences are characterized to find homology between known cell-binding components and the phage sequences. For example, the endolysin of Listeria phage is deduced from Listeria phage sequences when compared to other endolysin sequences. Thus, the sequence of a Listeria-specific cell-binding domain is selected or designed and used as an aspect of an MDP to detect Listeria.
[0141] Some embodiments of the present invention exploit the binding specificity of recombinant MDPs for rapid and sensitive targeting to bind and facilitate detection of bacteria of interest.
[0142] Recombinant Microbial Detection Probes As described in more detail herein, the compositions, methods, systems and kits of the invention may include microbial detection probes (MDPs) for use in detecting pathogenic microorganisms. In certain embodiments, the invention includes recombinant MDPs having a cell binding component (CBC) and an indicator or reporter gene.
[0143] In some embodiments, the gene fragment encoding the CBC is isolated from a bacteriophage specific to the target of detection. In some embodiments, the CBC is derived from a bacteriophage (e.g., T7, T4 or another similar phage). The bacteriophage CBC can also be derived from T4-like, T7-like, ViI, ViI-like, AR1, A511, A118, A006, A500, PSA, P35, P40, B025, B054, A97, phiSM101, phi3626, CBA120, SPN1S, 10, epsilon15, P22, LipZ5, P40, vB_LmoM_AG20, P70, A511, P4W, K, Twort, or SA97. In some embodiments, the CBC can be the CBD of an endolysin or the part thereof that acts as a functional binding domain. A functional binding domain may be a conserved amino acid sequence within the CBD that is responsible for binding function / bacterial specificity. In other embodiments, the CBC may be a functional binding domain or another type of protein encoded by the bacteriophage genome, including, but not limited to, o-spanins, tail spikes, and tail fibers. In some embodiments, the o-spanin may be RZ1.
[0144] In some embodiments, the CBC can be back-translated into DNA and synthesized for cloning into an indicator fusion protein. Small MDPs allow more molecules to bind to one cell and generate a signal. With this in mind, smaller indicator gene products may be preferred (but note that even really large MDPs can be much smaller than antibodies). OpLuc and NANOLUC® proteins are only about 20 kDa (approximately 500-600 bp to encode), while FLuc is about 62 kDa and requires approximately 1,700 bp to encode. For comparison, the T7 genome is approximately 40 kbp, while the T4 genome is approximately 170 kbp. In some embodiments, the CBC is cloned into a NANOLUC® fusion plasmid. In some embodiments, the fusion plasmid is generated by mutation of a stop codon and insertion of a restriction endonuclease site via site-directed mutagenesis. In some embodiments, the CBC gene fragment is cloned into a restriction enzyme site of the fusion plasmid to generate the MDP construct. The MDP construct is transformed into E. coli and cultured in LB medium. Expression of the MDP can be induced by addition of an appropriate inducer. In one embodiment, addition of isopropyl 1β-D-1 thiogalactopyranoside (IPTG) can be used to induce expression of the MDP. In some embodiments, the culture can be shaken to induce expression of the MDP.
[0145] In addition, the indicator should produce a high signal-to-background ratio and be easily detectable in a timely manner. Promega's NANOLUC® is a modified Oplophorus gracilirostris (deep-sea shrimp) luciferase. In some embodiments, Promega's NANO-GLO®, NANOLUC® in combination with an imidazopyrazinon substrate (furimazine) can provide a robust signal with low background.
[0146] In some MDP embodiments, an indicator moiety is fused to the CBC. The indicator can be any of a variety of biomolecules. The indicator can be a detectable product, or an enzyme that produces a detectable product, or a cofactor for an enzyme that produces a detectable product. In some embodiments, the indicator moiety of the MDP is a reporter (e.g., a detectable enzyme). The indicator gene product can emit light and / or be detectable by a color change. A variety of suitable enzymes are commercially available (e.g., alkaline phosphatase (AP), horseradish peroxidase (HRP), or luciferase (Luc)). For example, in one embodiment, the indicator is a luciferase enzyme. Various types of luciferases can be used. In alternative embodiments, and as described in more detail herein, the luciferase is one of Oplophorus luciferase, firefly luciferase, Lucia luciferase, Renilla luciferase, or an engineered luciferase. In some embodiments, the luciferase is from Oplophorus. In some embodiments, the indicator is a genetically modified luciferase, such as NANOLUC®. Other engineered luciferases or other enzymes that generate a detectable signal may also be suitable indicator moieties. In some embodiments, these enzymes may serve as the indicator moiety.
[0147] Alternative MDP embodiments include conjugated indicator moieties. For example, FITC can be conjugated to CBD to create functional MDP. In some embodiments, MDP can include additional moieties or segments, such as segments for binding to solid support, which facilitates separating bound MDP from unbound MDP. Conjugation with indicator moieties does not affect the affinity of the CBD for microorganisms.
[0148] The compositions of the invention may include one or more MDPs derived from one or more wild-type infectious agents (e.g., bacteriophages) and one or more indicator moieties. In some embodiments, the compositions may include a cocktail of different MDPs that may generate the same or different indicator signals. That is, a composition for detecting a microorganism may include all the same or different MDPs.
[0149] The MDP applied as described above includes a cell binding component (CBC) that facilitates specific detection of microorganisms based on the specificity of the CBC. In another approach that can utilize CBC for specificity, the previously described assay using recombinant bacteriophage that recognizes and binds specific bacteria can be used. The recombinant bacteriophage assay can be performed in a device as described further herein.
[0150] Recombinant bacteriophage As described in more detail herein, the device, method, system and kit of the present invention includes a recombinant bacteriophage for use in detecting a microorganism of interest. The recombinant bacteriophage is contained in a first compartment of the device disclosed above. In some embodiments, the present invention may include a composition including a recombinant bacteriophage having an indicator gene integrated into the genome of the bacteriophage. In some embodiments, the indicator gene is operably linked to a promoter that is not the native promoter of the bacteriophage. In some embodiments, the indicator gene is operably linked to a native promoter of the bacteriophage. The recombinant bacteriophage containing the indicator or reporter gene is also referred to as an indicator bacteriophage in this disclosure.
[0151] Recombinant bacteriophage may include a reporter or indicator gene. In certain embodiments of the bacteriophage, the indicator gene does not encode a fusion protein. For example, in certain embodiments, expression of the indicator gene during bacteriophage replication after infection of a host bacterium results in a soluble indicator protein product. In certain embodiments, the indicator gene may be inserted into the late gene region of the bacteriophage. Late genes code for structural proteins and are therefore generally expressed at higher levels than other phage genes. The late gene region may be a class III gene region and may include a gene for a major capsid protein.
[0152] Some embodiments include designing (and optionally preparing) sequences for homologous recombination downstream of the major capsid protein gene. Other embodiments include designing (and optionally preparing) sequences for homologous recombination upstream of the major capsid protein gene. In some embodiments, the sequences include a codon-optimized reporter gene followed by an untranslated region. The untranslated region may include a phage late gene promoter and a ribosome entry site.
[0153] In some embodiments, the indicator bacteriophage is derived from A511, P100, Listeria phage LMTA-94, LMA4, LMA8, T7, T4 or another similar phage. The indicator bacteriophage also has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% affinity to a T7, T7-like, T4, T4-like, P100virus, Cronobacter-specific, Salmonella-specific, Listeria-specific, or Staphylococcus-specific bacteriophage, ViI, or ViI-like (or Vi1 virus-like (according to GenBank / NCBI) bacteriophage) It may be derived from P100virus, T4-like, T7-like, ViI, ViI-like, Cronobacter-specific, Salmonella-specific, Listeria-specific or Staphylococcus-specific bacteriophage with a homologous genome, or another bacteriophage. In some embodiments, the indicator phage is derived from a bacteriophage that is highly specific for a particular pathogenic microorganism. Genetic modification may avoid the deletion of wild-type genes, so the modified phage may remain more similar to wild-type bacteriophage than many commercially available phages. Bacteriophage derived from the environment may be specific for bacteria found in the environment, and thus genetically distinct from commercially available phages.
[0154] Furthermore, phage genes considered non-essential may have unrecognized functions. For example, apparently non-essential genes may have important functions in increasing burst size, such as clever cutting, fitting, or trimming functions in assembly. Therefore, deleting genes and inserting indicators may be detrimental. Most phages may package DNA that is a few percent larger than their native genome. In this consideration, smaller indicator genes may be a more suitable choice for modifying bacteriophages, especially those with smaller genomes. OpLuc and NANOLUC® proteins are only about 20 kDa (about 500-600 bp to code for), while FLuc is about 62 kDa (about 1,700 bp to code for). For comparison, the genome of T7 is about 40 kbp, while the genome of T4 is about 170 kbp, and the genome of Cronobacter, Salmonella or Staphylococcus specific bacteriophage is about 157 kbp. Furthermore, the reporter gene should not be endogenously expressed by the bacteria (i.e., not part of the bacterial genome), should generate a high signal-to-background ratio, and should be easily detectable in a timely manner. Promega's NANOLUC® is a modified Oplophorus gracilirostris (deep sea shrimp) luciferase. In some embodiments, Promega's NANO-GLO®, NANOLUC® in combination with an imidazopyrazinon substrate (furimazine) can provide a robust signal with low background.
[0155] In some indicator phage embodiments, the indicator gene may be inserted into a non-translated region to avoid disruption of a functional gene, leaving the wild-type phage gene intact, which may result in greater fitness when infecting non-laboratory strains of bacteria. Additionally, including stop codons in all three reading frames may help increase expression by reducing read-through (also known as leaky expression). This strategy may also eliminate the possibility of low levels of fusion protein being made that appear as a background signal (e.g., luciferase) that cannot be separated from the phage.
[0156] The indicator gene may express various biomolecules. The indicator gene is a gene that expresses a detectable product or an enzyme that produces a detectable product. For example, in one embodiment, the indicator gene encodes a luciferase enzyme. Various types of luciferases may be used. In alternative embodiments, and as described in more detail herein, the luciferase is one of Oplophorus luciferase, firefly luciferase, Lucia luciferase, Renilla luciferase, or an engineered luciferase. In some embodiments, the luciferase gene is from Oplophorus. In some embodiments, the indicator gene is a genetically modified luciferase gene, such as NANOLUC®.
[0157] Thus, in some embodiments, the invention includes a genetically modified bacteriophage that includes a non-bacteriophage indicator gene in the late (class III) gene region. In some embodiments, the non-native indicator gene is under the control of a late promoter. Using a viral late gene promoter ensures that the reporter gene (e.g., luciferase) is not only expressed at high levels like viral capsid proteins, but is also not silenced like endogenous bacterial genes or even early viral genes.
[0158] In some embodiments, the late promoter is a P100virus, T4-like, T7-like or ViI-like promoter, or another phage promoter similar to that found in the selected wild-type phage, i.e., without genetic modification. The late gene region may be a class III gene region and the bacteriophage may be derived from a T7, T4, T4-like, ViI, ViI-like, Cronobacter, Salmonella, Staphylococcus, Listeria or S. aureus-specific bacteriophage, or another naturally occurring bacteriophage having a genome with at least 70, 75, 80, 85, 90 or 95% homology to a T7, T4, T4-like, ViI, ViI-like or Cronobacter, Salmonella, Staphylococcus, Listeria or S. aureus-specific bacteriophage.
[0159] The genetic modification to the bacteriophage may include the insertion, deletion, or replacement of small fragments of nucleic acid, substantial portions of genes, or entire genes. In some embodiments, the inserted or replaced nucleic acid comprises a non-native sequence. The non-native indicator gene may be inserted into the bacteriophage genome such that it is under the control of a bacteriophage promoter. In some embodiments, the non-native indicator gene is not part of a fusion protein. That is, in some embodiments, the genetic modification may be configured such that the indicator protein product does not contain the wild-type bacteriophage polypeptide. In some embodiments, the indicator protein product is soluble. In some embodiments, the invention includes a method for detecting a bacterium of interest, the method including incubating a test sample with such a recombinant bacteriophage.
[0160] In some embodiments, expression of the indicator gene in the progeny bacteriophage after infection of the host bacterium results in a free soluble protein product. In some embodiments, the non-native indicator gene is not linked to a gene encoding a phage structural protein and therefore does not result in a fusion protein. Unlike systems that use a fusion of a detection moiety to a capsid protein (i.e., a fusion protein), some embodiments of the present invention express a soluble indicator or reporter (e.g., a soluble luciferase). In some embodiments, the indicator or reporter ideally does not include the bacteriophage structure. That is, the indicator or reporter is not bound to the phage structure. Thus, the indicator or reporter gene is not fused to other genes in the recombinant phage genome. This can greatly increase the sensitivity of the assay (to a single bacterium) and simplify the assay, allowing the assay to be completed in less than an hour for some embodiments, as opposed to the several hours due to the additional purification steps required for constructs that generate detectable fusion proteins. Furthermore, fusion proteins may be less active than soluble proteins due to protein folding constraints that may, for example, alter the conformation of the enzyme active site or access to substrates.
[0161] Furthermore, fusion proteins by definition limit the number of moieties attached to a protein subunit in the bacteriophage. For example, the use of a commercially available system designed to act as a platform for fusion proteins results in approximately 415 copies of the fusion moiety in each T7 bacteriophage particle, corresponding to approximately 415 copies of the gene 10B capsid protein. Without this constraint, infected bacteria would be expected to express more copies of the detection moiety (e.g., luciferase) than can fit on the bacteriophage. Furthermore, large fusion proteins (e.g., capsid-luciferase fusions) may inhibit assembly of the bacteriophage particle, thus resulting in fewer bacteriophage progeny. Thus, a soluble, non-fused indicator gene product may be preferred.
[0162] In some embodiments, the indicator phage encodes a reporter, such as a detectable enzyme. The indicator gene product may produce light and / or be detectable by a color change. A variety of suitable enzymes are commercially available (e.g., alkaline phosphatase (AP), horseradish peroxidase (HRP), or luciferase (Luc)). In some embodiments, these enzymes may serve as the indicator moiety. In some embodiments, firefly luciferase is the indicator moiety. In some embodiments, Oplophorus luciferase is the indicator moiety. In some embodiments, NANOLUC® is the indicator moiety. Other engineered luciferases or other enzymes that generate a detectable signal may also be suitable indicator moieties.
[0163] In some embodiments, the use of soluble detection moieties eliminates the need to remove contaminating parent phage from the lysate of the infected sample cells. With a fusion protein system, any bacteriophage used to infect sample cells has a detection moiety attached and is indistinguishable from daughter bacteriophage that also contain the detection moiety. Because detection of sample bacteria relies on detection of newly created (de novo synthesized) detection moieties, the use of fusion constructs requires an additional step to separate the old (parent) moiety from the newly created (daughter bacteriophage) moiety. This can be accomplished by washing the infected cells multiple times prior to completion of the bacteriophage life cycle, inactivating excess parent phage after infection by physical or chemical means, and / or chemically modifying the parent bacteriophage with a binding moiety (e.g., biotin) that can then be bound and separated (e.g., by streptavidin-coated sepharose beads). However, even with all these attempts at removal, parent phage can persist when high concentrations of parent phage are used to ensure infection of a small number of sample cells, creating a background signal that can obscure detection of signal from progeny phage in infected cells.
[0164] In contrast, with the soluble detection moieties expressed in some embodiments of the invention, purification of the parent phage from the final lysate is not necessary because the parent phage does not have any detection moieties attached. Thus, any detection moieties present after infection must be newly generated, indicating the presence of an infected bacterium or bacteria. To take advantage of this benefit, the generation and preparation of parent phage can include purification of the phage from any free detection moieties generated during the generation of the parent bacteriophage in bacterial culture. Standard bacteriophage purification techniques can be used to purify some embodiments of phages according to the invention (e.g., sucrose density gradient centrifugation, cesium chloride isopycnic density gradient centrifugation, HPLC, size exclusion chromatography, etc.). and dialysis or derived techniques (e.g., Amicon brand concentrators - Millipore, Inc.). Cesium chloride isopycnic ultracentrifugation can be used as part of the preparation of recombinant phage of the invention to separate parent phage particles from contaminating luciferase protein produced during propagation of the phage in the bacterial host. In this way, the parent recombinant bacteriophage of the invention are substantially free of any luciferase produced during production in the bacteria. Removal of residual luciferase present in the phage stock can substantially reduce the background signal observed when the recombinant bacteriophage is incubated with a test sample.
[0165] In some embodiments of modified bacteriophages, the late promoter (class III promoter, e.g., from Listeria-specific phage, T7, T4, or ViI) has high affinity for the RNA polymerase of the same bacteriophage that transcribes the genes of structural proteins that are assembled into the bacteriophage particle. These proteins are the most abundant proteins made by the phage, since each bacteriophage particle contains tens or even hundreds of copies of these molecules. The use of a viral late promoter can optimally ensure high levels of expression of the luciferase detection moiety. The use of a late viral promoter derived from, specific to, or active under the original wild-type bacteriophage from which the indicator phage is derived (e.g., Listeria-specific phage with a T4, T7, or ViI-based system, T4, T7, or ViI late promoters) can even further ensure optimal expression of the detection moiety. The use of standard bacterial (non-viral / non-bacteriophage) promoters can in some cases be detrimental to expression because these promoters are often downregulated during bacteriophage infection (as the bacteriophage prioritizes bacterial resources for phage protein production). Thus, in some embodiments, the phage is engineered to encode and express high levels of a soluble (free) indicator moiety, preferably using a location in the genome that does not limit expression to the number of subunits of the phage structural components.
[0166] The compositions of the invention may include one or more wild-type or genetically modified bacteriophages (e.g., bacteriophages) and one or more indicator genes. In some embodiments, the compositions may include a cocktail of different indicator phages that may encode and express the same or different indicator proteins. In some embodiments, the cocktail of bacteriophages includes at least two different types of recombinant bacteriophages.
[0167] Device Embodiments of the present invention relate to methods of detecting a microorganism of interest using a self-contained device. The device includes a solid support that can be used to collect a sample containing the microorganism of interest. In some embodiments, the device according to the invention includes a tube with separate compartments, either arranged consecutively or in a branched configuration (e.g., the "ears" of a tube). The device can include multiple compartments that can be configured for mixing of reagents and variation in timing of method steps. In some embodiments, the top or upper compartment of the tube contains recombinant bacteriophage and a substrate compartment is below the bacteriophage compartment. In some embodiments, the tube contains growth medium.
[0168] In the simplest embodiment, a first compartment contains recombinant bacteriophage and a second compartment contains a substrate or color reagent. In some such embodiments, both reagents are mixed simultaneously with the sample (captured on the solid support). In other embodiments, a sample is first added to the first compartment to initiate infection. After a period of time, a conduit to the second compartment is opened to allow the substrate or color reagent to be added and mixed with the infected sample.
[0169] In alternative embodiments, the first compartment contains a microbial detection probe (MDP) and the second compartment contains a substrate or color reagent. In some such embodiments, both reagents are mixed simultaneously with the sample (captured on the solid support). In other embodiments, the sample is added to the first compartment first. After a period of time, a conduit to the second compartment is opened to allow the substrate or color reagent to be added and mixed with the infected sample.
[0170] In some embodiments, a seal separates adjacent compartments and the user breaks the seal, causing both substrate and phage to simultaneously encounter the swab. Luciferase is produced and reacts with the substrate to produce a detectable signal.
[0171] In some embodiments, the substrate compartment may be located between the medium compartment and the recombinant bacteriophage compartment, and when a user breaks the seal and applies a reagent to a sample captured on the solid support, both reagents are applied simultaneously.
[0172] In an alternative embodiment, the substrate compartment is disposed between the medium compartment and the MDP compartment, and when a user breaks the seal and applies reagents to a sample captured on the solid support, both reagents are applied simultaneously.
[0173] In some embodiments, the solid support is a tube and the substrate or color developer is added to the bottom of the tube; the solid support is pushed to the bottom to initiate a reaction between the enzyme and substrate or other reporter and paired reagent. The solid support may be attached to a shaft for ease of handling.
[0174] The following figures provide illustrative examples of embodiments of the present invention.
[0175] In one embodiment, the present disclosure provides a self-contained microbial detection device system. Figure 12 shows one embodiment of a device 100. The device includes a solid support 16 and a container that includes three compartments. Each of the compartments is separated by a snap action seal. The first compartment 10 contains phage, the second compartment 12 contains a substrate, and the third compartment 14 contains a medium. This device allows the phage and substrate to be incubated simultaneously with the sample.
[0176] Figure 13 shows a second embodiment of a device 200. The device includes a solid support 26 and a container containing three compartments. Each of the compartments is separated by a snap action seal. The first compartment 20 contains phages, the second compartment 22 contains medium, and the third compartment 24 contains a substrate. In an embodiment, using the device shown in Figure 13, the sample is first incubated with the phage before incubating with the substrate. In a further embodiment using the device shown in Figure 13, the solid support is immersed in medium before collecting the sample.
[0177] Figure 14 shows a third embodiment of a device 300. The device includes a solid support 36 and a container containing three compartments. Each of the compartments is separated by a snap action seal. The first compartment 30 contains the medium, the second compartment 32 contains the phage, and the third compartment 34 contains the substrate. In an embodiment, using the device shown in Figure 14, the sample is first incubated with the phage before incubating with the substrate. In a further embodiment using the device shown in Figure 14, the solid support is dried before collecting the sample.
[0178] FIG. 15 shows a fourth embodiment of a device 400. The device includes a solid support 46 and a container containing three compartments. Each of the compartments is separated by a snap action seal. The first compartment 40 contains the medium, the second compartment 42 contains the phage, and the third compartment 46 contains the substrate. The device has a stop-lock mechanism for stepwise mixing of reagents. In an embodiment, using the device shown in FIG. 15, the sample is first incubated with the phage before incubating with the substrate. In a further embodiment using the device shown in FIG. 15, the solid support is immersed in the medium before collecting the sample.
[0179] FIG. 16 shows a fifth embodiment of a device 500. The device includes a solid support 56 and a container containing three compartments. Each of the compartments is separated by a snap action seal. The first compartment 50 contains the medium, the second compartment 52 contains the phage, and the third compartment 54 contains the substrate. The device has a stop-lock mechanism for stepwise mixing of reagents. In an embodiment, using the device shown in FIG. 16, the sample is first incubated with the phage before incubating with the substrate. In a further embodiment using the device shown in FIG. 16, the solid support is dried before collecting the sample.
[0180] FIG. 17 describes a method for detecting microorganisms, comprising: (i) enriching a sample overnight; (ii) collecting the overnight enriched sample using a solid support from a self-contained device; (iii) infecting the sample with phage contained within a compartment of the self-contained device; and (iv) detecting the presence of a microorganism by reading / detecting a signal generated by the infection step.
[0181] In some embodiments, compartments contained in protrusions or branches from the central tube allow mixing of reagents from more than two directions, for example in the form of "ears." For example, two squeeze bulbs can be used to add media and then phage can be added sequentially or simultaneously to the main compartment, or other reagents can be added. Various arrangements of the other compartments with respect to the central compartment allow for the addition and mixing of different reagents to larger adjacent compartments.
[0182] Solid Support Coated with Cell-Binding Components As discussed above, the device of the present disclosure may include a solid support. A variety of solid supports may be used. In certain embodiments, the solid support may include a swab, a filter, a bead, a lateral flow strip, a filter strip, a filter disk, a filter paper, or a thin film designed for culturing cells (e.g., PetriFilm by 3M). In some embodiments, the solid support includes a plastic material. In some embodiments, the solid support includes polyethylene (PE), polypropylene (PP), polystyrene (PS), polylactic acid (PLA), and polyvinyl chloride (PVC). In some embodiments, the solid support is coated with a cell-binding component that has a high affinity for the microorganism to be detected. In some embodiments, the solid support is a polystyrene bead or a bead made of a similar or other material (e.g., polylactic acid), so that the bead can be coated with protein but does not react with other components in the assay.
[0183] In some embodiments, the beads are large enough so that multiple cell binding components (CBCs) that bind to a specific microorganism can be attached to the bead. The bead should also be of an appropriate size so that it initially fits into the tube of the device. For example, the beads can range in size from 0.1 to 100 mm, 1 to 10 mm, or 4 to 8 mm, or 6 to 7 mm in diameter. The amount of CBCs per solid support can vary. It generally depends on the size of the bead and also on the concentration of the bacteria in the sample. In some embodiments, the amount of CBCs on each bead is at least 5×10 7 , or at least 5 × 10 8 , or at least 5 × 10 10 , or at least 5 × 10 13 , or at least 5 × 10 14 , or at least 5 × 10 16 It may be a molecule.
[0184] The CBC coated on the solid support of the device can bind to the microorganism of interest with high affinity, thus enriching the amount of microorganism that the solid support can capture. For example, in certain embodiments, the CBC is highly specific for S. aureus, Listeria, Salmonella, or E. coli. In one embodiment, the CBC can distinguish S. aureus, Listeria, Salmonella, or E. coli in the presence of more than 100 other types of bacteria. In one embodiment, the CBC can distinguish a specific serotype within a species of bacteria (e.g., E. coli O157:H7) in the presence of more than 100 other types of bacteria. In certain embodiments, the method of using the device including the solid support coated with the CBC can be used to detect a specific type of one bacterium in the sample. In certain embodiments, the CBC detects as few as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 of a particular bacterium in the sample. Thus, in certain embodiments, the method may detect <10 cells (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 microorganisms), or <20, or <30, or <40, or <50, or <60, or <70, or <80, or <90, or <100, or <200, or <500, or <1000 cells) of the microorganism present in a sample.
[0185] In some embodiments, the CBC is a protein, also referred to in this disclosure as a microorganism detection protein. In some embodiments, the CBC is a protein that binds to the cell wall of gram-positive bacteria. In some embodiments, the CBC is a phage tail protein used to attach to the outer surface of specific microorganisms, including gram-negative bacteria. In some embodiments, the phage tail protein is a phage lambda tail protein. In some embodiments, the CBC is a protein produced by expressing a gene fragment isolated from a bacteriophage specific for detection of the microorganism.
[0186] In some embodiments, the CBC used to capture a particular type of microorganism may be derived from a particular bacteriophage, such as T7, T4, or another similar phage. In some embodiments, the CBC may be lysin encoded and expressed by the phage of the bacteria. The bacteriophage CBC may also be derived from T4-like, T7-like, ViI, ViI-like, AR1, A511, A118, A006, A500, PSA, P35, P40, B025, B054, A97, phiSM101, phi3626, CBA120, SPN1S, 10, epsilon15, P22, LipZ5, P40, vB_LmoM_AG20, P70, A511, P4W, K, Twort, or SA97.
[0187] In some cases, the CBC can be a receptor binding protein through which the phage can bind a specific bacterium. The interaction of the RBP with the bacterial cell surface determines the RBP specificity. In some phages, the RBP is located in the tail shaft, tail fiber, or tail spike. Phage tail fiber proteins play a role in both cell surface adsorption and polysaccharide degradation. Tail spike proteins are components of the tails of many bacteriophages. Tail spike proteins bind to the bacterial host cell surface and mediate bacterial host recognition. Thus, in some embodiments, the CBC can be the tail fiber, tail spike, of the bacteriophage specific for the microorganism.
[0188] In some embodiments, the CBC can be one or more of an endolysin, a holin, a spanin, or a functional binding domain thereof that can bind to the microorganism with high affinity. These three proteins are encoded by bacteriophages and together are responsible for progeny release during the phage lytic cycle. In some embodiments, the CBC comprises an endolysin cell wall binding domain ("CBD"), which allows the bacteriophage to recognize the bacterium with high affinity. In some embodiments, the CBC comprises a conserved amino acid sequence that is responsible for binding the microorganism. Typically, the CBD is located at the C-terminus, but can also be found as an N-terminus or in some cases as a central domain.
[0189] In some embodiments, the CBC may be a protein that shares substantial amino acid sequence identity with a protein selected from the group consisting of an endolysin, a holin, a spanin, an o-spanin (e.g., RZ1), a tail spike, and a tail fiber, or a functional binding domain thereof. A functional binding domain may be a conserved amino acid sequence within a polypeptide responsible for binding function / bacteria specificity. For example, the CBC may share at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% amino acid sequence identity with an endolysin (SEQ ID NO: 1; or YP_001468459) or the CBD of an endolysin (SEQ ID NO: 2), or any of the proteins known to have high affinity for the microorganism of interest. An exemplary method of expressing the CBD of an endolysin is shown in Example 6.
[0190] In some embodiments, the CBC can be reverse transcribed into DNA and synthesized for cloning into an expression vector. The CBC expression vector can be transformed into E. coli and cultured in LB medium. Expression of the CBC can be induced by the addition of an appropriate inducer. In one embodiment, the addition of isopropyl 1β-D-1 thiogalactopyranoside (IPTG) can be used to induce the fuming of the CBC.
[0191] Various methods for coating solid support are well known in the art. In one embodiment, the solid support can comprise streptavidin and biotinylated CBC, and the coating of the solid support comprises biotin-streptavidin interaction. In some cases, the CBC can be conjugated to amine to facilitate binding to avidin attached to the surface of the solid support.
[0192] Method of using a device for detecting microorganisms As noted herein, in certain embodiments, the invention may include a method of detecting the microorganism, comprising contacting the sample with a solid support such that the microorganism is captured on the solid support, contacting recombinant bacteriophage from the first compartment with the microorganism captured on the solid support, for example, by breaking a snap action seal of the first compartment. During and / or after the infection, the bacteriophage express the indicator gene to produce an indicator, which can be detected by various detection devices. In some embodiments, detection of the indicator may require the addition of a substrate that reacts with the indicator to produce a detectable signal. The presence of the signal indicates the presence of the microorganism in the sample.
[0193] In an alternative embodiment, the invention may include a method of detecting the microorganism, comprising contacting the sample with a solid support such that the microorganism is captured on the solid support, contacting an MDP from the first compartment with the microorganism captured on the solid support, for example, by breaking a snap action seal of the first compartment. The indicator portion of the MDP may be detected by a variety of detection devices. In some embodiments, detection of the indicator may require the addition of a substrate that reacts with the indicator to generate a detectable signal. The presence of the signal indicates the presence of the microorganism in the sample.
[0194] sampling In some embodiments, samples can be used directly in the detection method of the present invention without preparation, concentration, or dilution. For example, liquid samples, including but not limited to milk and juice, can be assayed directly. In other embodiments, samples can be diluted or suspended in a solution, including but not limited to a buffered solution or bacterial culture medium. Samples that are solid or semi-solid can be suspended in a liquid by chopping, mixing, or macerating the solid in the liquid. In some embodiments, samples should be maintained within a pH range that promotes CBC attachment to the host bacterial cells. In some embodiments, the preferred pH range can be suitable for bacteriophage attachment to bacterial cells. Samples should also contain appropriate concentrations of divalent and monovalent cations, including but not limited to Na+, Mg2+, and K+.
[0195] Preferably, throughout the detection assay, the sample is maintained at a temperature that maintains the viability of any pathogen cells present in the sample. During the step in which the bacteriophage is attached to the bacterial cells, it is preferred to maintain the sample at a temperature that promotes bacteriophage activity. Such a temperature is at least about 25°C and not more than about 45°C. In some embodiments, the sample is maintained at about 37°C. In some embodiments, the sample is subjected to gentle mixing or shaking during CBC binding or attachment.
[0196] The assay may include a variety of suitable non-inoculated control samples, for example, a non-inoculated control sample lacking bacteria, such as a food sample, may be assayed as a control for background signal levels.
[0197] Sampling can be performed using a variety of methods. In some embodiments, the sample, e.g., a food sample, is first liquefied and the solid support, e.g., the solid support or beads, is immersed in the liquid sample. In some embodiments, the solid support is first immersed in culture medium in a tube before sampling. In some embodiments, the solid support is dried before sampling. In some embodiments, the liquid sample is first cultured ("culture enrichment") for a period of time, e.g., less than 24 hours, less than 12 hours, less than 9 hours or less, less than 8 hours or less, less than 7 hours or less, less than 6 hours or less, less than 5 hours or less, less than 4 hours or less, less than 3 hours or less, or less than 2 hours of enrichment period.
[0198] In other embodiments, the sample may be enriched after capture of the microorganisms on the solid support. In some embodiments, the solid support with the microorganisms is incubated in a growth medium in the third compartment of the device to allow the microorganisms to expand in number. This step is called incubation enrichment. In such embodiments, the enrichment period may be up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours or longer, depending on the sample type and size.
[0199] In some embodiments of the methods of the present invention, the microorganisms can be detected without any isolation or purification of the microorganisms from the sample. For example, in certain embodiments, a sample containing one or more microorganisms of interest can be applied directly to the solid support and the assay is performed in the device.
[0200] infection The method disclosed herein includes the step of operating the device to contact the recombinant bacteriophage with the microorganism of interest. Upon contact of the microorganism, the bacteriophage replicates and expresses the indicator or reporter gene. See the section entitled "Recombinant Bacteriophage". The infection time, i.e., the period between when the sample is first contacted with the bacteriophage and when the substrate is added to the mixture, can vary depending on the type of bacteriophage and the concentration of the microorganism in the sample. Using a device in which the bacteria are captured on a solid support, the time required for infection can be significantly reduced. For example, while the infection time can be 1 hour or less, in standard assays where a solid support is not used to capture the bacteria, the infection is typically at least 4 hours, and in certain embodiments, the infection time of the methods disclosed herein is less than 6.0 hours, less than 5.0 hours, less than 4.0 hours, less than 3.0 hours, less than 2.5 hours, less than 2.0 hours, less than 1.5 hours, less than 1.0 hour, less than 45 minutes, or less than 30 minutes. In some embodiments, the infection time is about 1 hour, about 2 hours, or about 3 hours.
[0201] Signal generation The indicator is produced by expression of the indicator gene and can be detected using methods well known to those skilled in the art. For example, one or more signal generating components can be reacted with the indicator to generate a detectable signal. In some embodiments, the indicator can be a bioluminescent compound. If the indicator is an enzyme, the amplification of the detectable signal is obtained by reacting the enzyme with one or more substrates or additional enzymes and substrates to generate a detectable reaction product. In an alternative signal generating system, the indicator can be a fluorescent compound where enzymatic manipulation of the indicator is not required to generate the detectable signal. For example, fluorescent molecules including fluorescein and rhodamine, and their derivatives and analogs, are suitable for use as indicators in such systems. In yet another alternative embodiment, the indicator moiety can be a cofactor, and the amplification of the detectable signal is obtained by reacting the cofactor with the enzyme and one or more substrates or additional enzymes and substrates to generate a detectable reaction product. In some embodiments, the detectable signal is chromogenic. It is noted that the selection of a particular indicator is not critical to the present invention, and the indicator may either itself generate a detectable signal or may be instrument detectable or detectable in conjunction with one or more additional signal generating components (e.g., an enzyme / substrate signal generating system).
[0202] In some embodiments, the detecting step requires the addition of a substrate on which the indicator enzyme acts. Substrates can be added in a variety of ways. In some embodiments, the substrate is contained in a second compartment of the device, and breaking the snap-action seal causes the phage (in a first compartment of the device) and substrate to contact the microorganism (captured on the solid support) simultaneously. See FIG. 12. In some embodiments, the snap-action seal is broken sequentially, contacting the microorganism with the bacteriophage before contacting the substrate. See FIGS. 13A and 13B. In some embodiments, the method includes manipulating the stop-lock to allow staged mixing, such that the microorganism contacts the bacteriophage before contacting the substrate.
[0203] In some embodiments, the reaction between the indicator (e.g., luciferase) and the substrate may continue for 30 minutes or longer, and detection at various time points may be desirable to optimize sensitivity, hi some embodiments, luminometer readings may be taken initially and at 3 minute, or 5 minute, or 10 minute, or 15 minute intervals until the reaction is complete.
[0204] Signal detection Detection of the signal generated by the indicator may include detecting light emission. In some embodiments, the compartment of the device where the substrate is mixed with the test sample is transparent, so that any signal resulting from the infection and subsequent incubation with substrate is visible. In this case, the signal may be detected through the wall of the compartment. In some embodiments, the device containing the reacted sample is inserted into an instrument for detecting the resulting signal. In other embodiments, a detection instrument is used to scan the device containing the reacted sample.
[0205] In some embodiments, a luminometer can be used to detect the indicator (e.g., luciferase) (e.g., GloMax from Promega, Madison, Wis.). (登録商標) 20 / 20 and GloMax (登録商標)). In some embodiments, a spectrophotometer, CCD camera, or CMOS camera can be used to detect color changes and other light emissions. While absolute RLU is important for detection, a high signal-to-background ratio (e.g., >2.0, >2.5, or >3.0) is also required to ensure that single cells or small numbers of cells are detected. The background signal can be obtained by measuring a non-inoculated control sample that does not contain microorganisms, using the same procedure described above. In some embodiments, detection of a signal from the reporter or indicator gene can include the use of an instrument that uses, for example, photodiode or PMT (photomultiplier tube) technology. In some embodiments, a portable luminometer can be used to detect the signal. Suitable PMT portable luminometers are available from 3M (Maplewood, MN), BioControl (Seattle, WA), and Charm Science (Lawrence, MA). Suitable photodiode portable luminometers are available from Hygiena (Camarillo, CA) and Neogen (Lansing, MI). These portable luminometers typically produce much lower readings compared to traditional luminometers (GloMax or GloMax 20 / 20) for the same samples. As shown in the examples, numerous experiments indicate that the signal generated by the reaction was sufficient to be detected by these portable luminometers. The assay was repeated multiple times with different types of microorganisms, including L. monocytogenes and Salmonella, and similar results were observed each time. This indicates that the detection method using the device is sufficiently sensitive and robust. The ability to detect the microorganisms using these portable devices also provides convenience and versatility that is often lacking in detection methods using traditional non-portable detection devices.
[0206] Systems and kits of the present invention In some embodiments, the present invention includes a system (e.g., an automated system or kit) that includes components for carrying out the methods disclosed herein. In some embodiments, the system or kit according to the present invention includes an apparatus. The methods described herein may also utilize such a system or kit. Some embodiments described herein are particularly suitable for automation or kits, given the minimal amount of reagents and materials required to carry out the methods. In certain embodiments, each of the components of the kit may include a self-contained unit that is deliverable from a first site to a second site.
[0207] In some embodiments, the present invention includes a system or kit for rapid detection of a microorganism of interest in a sample. The system or kit may in certain embodiments include an apparatus as described above, where the solid support includes a cell binding component as described above, and a signal detection component capable of detecting the indicator gene product generated from infecting the sample with the recombinant bacteriophage. In some embodiments, the signal detection component is a portable device. In some embodiments, the signal detection component is a portable luminometer.
[0208] Thus, in certain embodiments, the invention may include a system or kit for rapid detection of a microorganism of interest in a sample comprising: a device comprising a first compartment containing a recombinant bacteriophage having a genetic construct inserted into the bacteriophage genome, wherein the construct comprises a promoter and an indicator gene. The system or kit further comprises a second compartment containing a substrate and / or a third compartment containing a medium. One or more of these compartments are sealed and separated from other parts of the device by a snap-action seal, and breaking the snap-action seal causes contents from the compartment to exit the compartment and mix with the sample.
[0209] In some embodiments, the system may include components for isolating the microorganism of interest from other components in the sample.
[0210] In some systems and / or kits, the same components may be used for multiple steps. In some embodiments, the steps are automated or controlled by a user via computer input and / or a liquid handling robot performs at least one step. In computerized systems, the system may be fully automated, semi-automated, or directed by a user via a computer (or some combination of these).
[0211] These systems and kits of the invention include various components. As used herein, the term "component" is broadly defined and includes any suitable device or collection of suitable devices for carrying out the described method. The components need not be integrally connected or mounted relative to each other in any particular manner. The invention includes any suitable arrangement of the components relative to each other. For example, the components need not be in the same space. However, in some embodiments, the components are connected to each other in an integral unit. In some embodiments, the same component may perform multiple functions.
[0212] Computer system and computer readable medium In certain embodiments, the present invention may include a system. The system may include at least some of the compositions of the present invention. Also, the system may include at least some of the components for carrying out the method. In certain embodiments, the system is formulated as a kit. Thus, in certain embodiments, the present invention may include a system for rapid detection of a microorganism of interest in a sample. The system may include at least some of the compositions of the present invention. Also, the system may include at least some of the components for carrying out the method. In certain embodiments, the system is formulated as a kit. Thus, in certain embodiments, the present invention may include a system for rapid detection of a microorganism of interest in a sample, comprising an apparatus as described above. For example, the apparatus may include a first compartment comprising a recombinant bacteriophage having a genetic construct inserted into the bacteriophage genome, wherein the construct comprises a promoter and an indicator gene; and wherein the solid support comprises a first compartment comprising a cell binding component. In some embodiments, the system also comprises a portable detection device.
[0213] The system may be embodied in the form of a computer system, as described in the present technology or any of its components. Representative examples of computer systems include general purpose computers, programmed microprocessors, microcontrollers, peripheral integrated circuit elements, and other devices or arrangements of devices capable of implementing the steps constituting the methods of the present technology.
[0214] The computer system may include a computer, an input device, a display unit, and / or the Internet. The computer may further include a microprocessor. The microprocessor may be connected to a communication bus. The computer may also include a memory. The memory may include a random access memory (RAM) and a read-only memory (ROM). The computer system may further include a storage device. The storage device may be a hard disk drive or a removable storage device (e.g., a floppy disk drive, an optical disk drive, etc.). The storage device may also be other similar means for loading computer programs or other instructions into the computer system. The computer system may also include a communication unit. The communication unit allows the computer to connect to other databases and the Internet through an I / O interface. The communication unit allows the transfer of data to and receipt of data from other databases. The communication unit may include a modem, an Ethernet card, or any similar device that allows the computer system to connect to databases and networks (e.g., LAN, MAN, WAN, and Internet). The computer system may thus facilitate input from a user through input devices accessible to the system via an I / O interface.
[0215] A computing device typically includes an operating system that provides executable program instructions for the general management and operation of the computing device, and typically includes a computer-readable storage medium (e.g., a hard disk, random access memory, read-only memory, etc.) that stores instructions that, when executed by a server's processor, cause the computing device to perform its intended functions. Suitable implementations of such operating systems and the general functionality of such computing devices are known or commercially available and are readily implemented by those of skill in the art, especially in light of the disclosure herein.
[0216] The computer system executes a set of instructions stored in one or more memory devices to process input data. The memory devices may also hold data or other information as described. The memory devices may be in the form of information sources or physical memory devices present in a processing machine.
[0217] The environment may include various data stores and other memory and storage media as discussed above. These may reside in various locations (e.g., in storage media local to (and / or residing in) one or more of the computers, or remote from any or all of the computers across a network). In a particular group of embodiments, the information may reside on a storage area network ("SAN") with which those skilled in the art are familiar. Similarly, any necessary files for performing the functions ascribed to the computers, servers, or other network devices may be stored locally and / or remotely, as appropriate. Where the system includes computing devices, each such device may include hardware elements that may be electrically coupled via a bus, including, for example, at least one central processing unit (CPU), at least one input device (e.g., a mouse, keyboard, controller, touch screen, or keypad), and at least one output device (e.g., a display device, printer, or speaker). Such a system may also include one or more storage devices, such as disk drives, optical storage devices, and solid-state storage devices, such as random access memory ("RAM") or read-only memory ("ROM"), as well as removable media devices, memory cards, flash cards, and the like.
[0218] Such devices may also include computer-readable storage media readers, communication devices (e.g., modems, network cards (wireless or wired), infrared communication devices, etc.), and working memory as described above. The computer-readable storage media readers may be connected to or configured to accept computer-readable storage media representing remote, local, fixed, and / or removable storage devices, as well as storage media for temporarily and / or more permanently containing, storing, transmitting, and retrieving computer-readable information. The systems and various devices also typically include many software applications, modules, services, or other elements located within at least one working memory device, including operating systems and application programs (e.g., client applications or web browsers). It should be recognized that alternative embodiments may have many variations from those described above. For example, customized hardware may also be used, and / or specific elements may be implemented in hardware, software (including portable software (e.g., applets)), or both. Additionally, connections to other computing devices (e.g., network input / output devices) may be used.
[0219] Non-transitory storage media and computer readable media for containing the code or portions of the code may include any suitable media known or used in the art, including storage media and communication media, including but not limited to volatile and non-volatile, removable and non-removable media implemented in any method or technology for storage and / or transmission of information, such as computer readable instructions, data structures, program modules, or other data, including RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disk (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium that can be used to store the desired information and that can be accessed by the system device. Based on the above disclosure and teachings provided herein, one skilled in the art will recognize other ways and / or methods for implementing the various embodiments.
[0220] A computer-readable medium may include, but is not limited to, electronic, optical, magnetic, or other storage devices capable of providing computer-readable instructions to a processor. Other examples include, but are not limited to, floppy disks, CD-ROMs, DVDs, magnetic disks, memory chips, ROMs, RAMs, SRAMs, DRAMs, content addressable memories ("CAMs"), DDRs, flash memories (e.g., NAND Flash or NOR Flash), ASICs, configured processors, optical storage media, magnetic tapes or other magnetic storage media, or any other media from which a computer processor may read instructions. In one embodiment, the computing device may include a single type of computer-readable medium (e.g., random access memory (RAM)). In other embodiments, the computing device may include two or more types of computer-readable media (e.g., random access memory (RAM), disk drives, and caches). The computing device may be in communication with one or more external computer-readable media (e.g., an external hard disk drive, or an external DVD or Blu-ray drive).
[0221] As discussed above, the embodiments include a processor configured to execute computer-executable program instructions and / or access information stored in memory. The instructions may include processor-specific instructions generated by a compiler and / or interpreter from code written in any suitable computer programming language, including, for example, C, C++, C#, Visual Basic, Java, Python, Perl, JavaScript, and ActionScript (Adobe Systems, Mountain View, Calif.). In one embodiment, the computing device includes a single processor. In other embodiments, the device includes two or more processors. Such processors may include microprocessors, digital signal processors (DSPs), application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), and state machines. Such processors may include programmable electronic devices (e.g., PLCs), programmable interrupt controllers (PICs), programmable logic devices (PLDs), programmable read-only memories (PROMs), electronically programmable read-only memories (EPROMs or EEPROMs), and the like. or other similar devices.
[0222] The computing device includes a network interface. In some embodiments, the network interface is configured to communicate over a wired or wireless communication link. For example, the network interface may enable communication over a network via Ethernet, IEEE 802.11 (Wi-Fi), 802.16 (Wi-Max), Bluetooth, infrared, etc. As another example, the network interface may enable communication over a network (e.g., CDMA, GSM, UMTS, or other cellular communication network). In some embodiments, the network interface may enable communication over a network such as a Universal Serial Bus (USB), 1394, or other standard with another device. A network interface may allow point-to-point connections via FireWire, serial or parallel connections, or similar interfaces. Some embodiments of suitable computing devices may include two or more network interfaces for communication over one or more networks. In some embodiments, the computing device may include a data store in addition to or in place of the network interfaces.
[0223] Some embodiments of a suitable computing device may include or be in communication with a number of external or internal devices, such as a mouse, a CD-ROM, a DVD, a keyboard, a display, an audio speaker, one or more microphones, or any other input or output device. For example, the computing device may be in communication with a variety of user interface devices and displays. The displays may use any suitable technology, including, but not limited to, LCD, LED, CRT, etc.
[0224] The set of instructions for execution by the computer system may include various commands that instruct a processing machine to perform particular tasks (e.g., steps constituting the methods of the present technology). The set of instructions may be in the form of a software program. Moreover, the software may be in the form of a collection of separate programs, a program module with a larger program, or a portion of a program module, as in the present technology. The software may also include modular programming in the form of object-oriented programming. The processing of input data by the processing machine may be in response to user commands, results of previous processing, or a request made by another processing machine.
[0225] While the present invention has been disclosed with reference to certain embodiments, many modifications, variations and alterations to the described embodiments are possible without departing from the scope and spirit of the invention, as defined in the appended claims. Thus, the present invention is not intended to be limited to the above-described embodiments, but has full scope defined by the language of the following claims and equivalents thereof. EXAMPLES
[0226] The following examples illustrate, but do not limit, the invention, describing detection of low numbers of cells, and even single bacteria, with reduced time to results.
[0227] Example 1. Construction of recombinant MDP for detection of Staphylococcus aureus A gene fragment encoding CBC was isolated from Staphylococcus phage Twort (GenBank: CAA 69021.1), reverse translated into DNA, and commercially synthesized for cloning into NANOLUC® fusion plasmid. His-NANOLUC-pET-15b fusion plasmid was generated by mutating the stop codon and inserting a restriction endonuclease XhoI site via site-directed mutagenesis. The CBC gene fragment encoding 75 amino acids was then cloned into the BamHI-XhoI restriction enzyme sites of HIS-NANOLUC-pET15b plasmid, resulting in the N-terminal NANOLUC®-S. Aureus CBC construct (MDP). The NANOLUC®-CBC construct was transformed into E. coli strain BL21 (DE3) pLysS. The transformed cells were grown in liquid Luria-Bertani (LB) medium at 37°C to an optical density (OD) of 0.5-1.0. Expression of the MDP was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG). The culture was incubated with shaking at 37°C for 5 hours.
[0228] Example 2. MDP-mediated bacterial detection using spin column filters In an exemplary experiment, S. aureus A300 was grown in Luria-Bertani Broth (LB) with shaking at 37° C. NANOLUC®-CBC was diluted to 1 μg / ml.
[0229] For each 1 mL of sample, 0.1 mL was added to the filters in triplicate. The filters were centrifuged at 600 g for 1 min. Then, 40 μL each of the NANOLUC®-CBC fusion proteins was added to each filter, followed by incubation at room temperature for 15 min. The filters were washed twice by adding 400 μL PBS, followed by centrifugation at 600 g for 1 min. Then, 150 μL LB was added, the suspension was transferred to a LUMITRAC® 200 96-well luminometer plate, and the luciferase assay was performed in a Promega luminometer by injecting 100 μL NANO-GLO®. The signal-to-background ratio was obtained by dividing the signal of each well by the average of the signals of the zero-cell controls.
[0230] Example 3 MDP-mediated bacterial detection using 96-well filter plates NANOLUC®-CBC fusion protein was diluted to 1 μg / ml. For each sample, 0.150 mL was added to multiple wells of a 96-well filter plate. The 96-well filter plate was centrifuged at 1200 rpm (263 rcf) for 3 minutes. 100 μL of 1 μg / ml NANOLUC®-CBC MDP was then added to each filter and incubated at room temperature for 15 minutes. The cells were washed twice by adding 300 μL PBS, followed by centrifugation at 600 g for 1 minute to remove unbound MDP. The luciferase assay was performed directly in the original filter plate using a Promega luminometer, injecting 100 μL NANO-GLO®, and the plate was read 3 minutes after the addition of NANO-GLO® substrate. Signal-to-background ratios were obtained by dividing the signal of each well by the average of the signal of the zero cell control.
[0231] Example 4 MDP-mediated Listeria detection using 96-well plates NANOLUC®-CBC fusion protein is diluted to 1 μg / ml. 100 μL samples are transferred to a 96-well plate coated with GtxListeria. The minimum cell concentration of the sample is 10 cells / ml. Samples with a cell concentration of less than 10 cells / mL are enriched before testing. Samples are then incubated in the 96-well plate for 30 minutes at 30° C. After incubation, the plate is washed three times with 300 μl PBS. 100 μL of 1 μg / ml NANOLUC®-CBC MDP is then added to each well and incubated for 15 minutes at room temperature. The cells are washed twice by adding 300 μL PBS to remove unbound MDP. The luciferase assay is performed directly in the original plate using a Promega luminometer by injecting 100 μL NANO-GLO® and reading the plate 3 minutes after addition of NANO-GLO® substrate. Signal to background ratios are obtained by dividing the signal of each well by the average of the signals of the zero cell controls.
[0232] Example 5. Detection of Microorganisms of Interest in Bacterial Cultures This example demonstrates that the use of the device described above can detect bacteria present in bacterial cultures.
[0233] Assembly of the Device 100 μl A511 / P100 phage cocktail (1.2×10e9 Pfu / mL) and 100 μl BHI medium + 1 mM CaCl2 were added to the top valve (first compartment) of the device. A511 / p100 phage is a phage that targets Listeria moncytogenes. A solid support press was used to press the top components of the device together. The device tube was filled with 900 μl BHI medium + 1 mM CaCl2. The solid support was then placed into the device tube to absorb some of the medium. The assembled device (including the solid support immersed in medium) was then kept at 4° C. overnight.
[0234] Growth of bacterial cultures Listeria moncytogenes was grown overnight in BHI medium (Beckton Dickinson, Sparks, MD, USA) in a shaking incubator. The overnight culture was then passaged in BHI medium at 37° C. to logarithmic growth phase. Logarithmic growth phase cells were then diluted to the appropriate cell number (see FIG. 3). The solid support was removed from the device and the diluted culture was added onto the solid support at the indicated CFU levels. The solid support with added bacteria or medium alone (control) was then placed back into the device tube and the tube was gently shaken to mix the contents (FIG. 3, Table 1).
[0235] In a similar experiment, two solid supports were spiked with 10 CFU of the above bacteria each. Non-inoculated samples served as controls. These samples were incubated overnight at 35°C to allow bacterial numbers to expand prior to infection and substrate exposure (Figure 3, Table 2).
[0236] infection The snap-valve was then broken by holding the solid support firmly and breaking the valve with the thumb and index finger. Phage (200 μl of 6×10e8 Pfu / mL) was expelled by squeezing the valve over the solid support tube. The contents in the solid support tube were mixed gently by swirling. The solid support was then placed in a 30° C. incubator for 4 hours for phage infection of the bacteria. The NanoGlo substrate (Promega, Madison, WI) was diluted 1:4 with 70% ethanol and 10 μl of the diluted substrate was added to the solid support tube. The contents of the device tube were mixed by vortexing and then allowed to sit for 3 minutes.
[0237] detection Three detection methods were used: the solid support tube was inserted into a Hygiena portable luminometer; 1 mL of the infection mixture was removed and transferred to a 1.5 mL microcentrifuge tube and read on a GloMax 20 / 20 luminometer ("GloMax 20 / 20"), and 150 μl of the infection mixture was transferred to a 96-well plate and read on a GloMax luminometer ("GloMax").
[0238] Detection was then performed on solid supports soaked in medium overnight at an infection time of 2 hours. The results are shown in Figure 5, Tables 1 and 2, and graphical representations of the results are shown in Figures 4A and 4B. The results show that without growth enrichment (no overnight incubation of the samples before capture on the solid support), the test is sensitive enough to detect 25,000 CFU with a Hygiena portable luminometer (Figure 4A) (readings of bacterial inoculated samples were all above the detection threshold of 10 relative light units (RLU) criterion for positive samples) and approximately 5,000 CFU with a GloMax 20 / 20 or GloMax (Figure 4B).
[0239] Example 6. Detection of Microorganisms in Turkey Samples Assembly of the Device The device was assembled as described in Example 1, except that the top valve was filled with 100 μl SEA1 / TSP1 phage cocktail (1.2×10e7 Pfu / mL) and 100 μl TSB medium (ThermoFisher Oxoid, Grand Island, NY USA) and the device tubing was filled with 1 mL TSB medium. SEA1 / TSP1 phage is a phage that targets Salmonella.
[0240] Bacterial inoculation of ground turkey meat. Salmonella cultures were grown overnight and diluted for high and low CFU samples as described below.
[0241] Test portions of 25g ground turkey were divided into three groups: uninoculated (5 samples), high inoculated (5 samples), and low inoculated (20 samples). Each of the 25g samples from the high inoculated group was inoculated with 2-10 CFU of Salmonella, and each of the low inoculated samples was inoculated with 0.2-2 CFU of Salmonella. Samples were then placed into filtered sample bags and stored at 4°C for 48-72 hours.
[0242] Bacterial enrichment in inoculated ground turkey meat. Pre-warmed TSB medium (41° C.) was added to each sample at a sample to medium ratio of 1:3. The samples were then blended in a STOMACHER® on high for 30 seconds and then incubated at 41° C. without shaking for 24 hours to enrich for bacteria in the samples.
[0243] sampling The test samples were obtained by immersing the solid support into each enriched sample and swirling for 10 seconds to allow maximum sample adsorption. The solid support was placed into the device tube filled with TSB medium. The tube was gently shaken to mix the contents in the tube, and then either infected immediately or placed at 37°C for an additional hour before infection.
[0244] infection The snap valve of the compartment containing the bacteriophage was then broken by holding the solid support firmly and breaking the valve with the thumb and index finger. The phage (200 μl of 6×10e6 Pfu / mL) was expelled into the tube by squeezing the valve at the top of the device tube. The contents in the device tube were mixed gently by swirling. The solid support was then placed in a 37° C. incubator for 30 minutes or 2 hours for phage infection of the bacteria. NanoGlo substrate (Promega, Madison, WI) was diluted 1:4 with 70% ethanol and 10 μl of the diluted substrate was added to the device tube. The contents of the device tube were mixed by vortexing and then left to stand for 3 minutes. Signal was detected as described in Example 1. Results from non-inoculated samples (control group) are shown in Table 3, and results from inoculated samples (experimental group) are shown in Table 4. A graphical representation of the above results is shown in Figures 6A and 6B.
[0245] The results show that each of the three detection devices used was able to detect all turkey samples that were positive for Salmonella after 24 hours of culture enrichment. The GloMax and GloMax 20 / 20 signals were much higher than the Hygiena luminometer. Incubation time (i.e., incubation of the solid support capturing the bacteria with medium prior to infection) and infection time are factors that can affect signal strength. Of the various additional incubation and infection times tested, 0 hour incubation time and 2 hour infection time produced the highest RLU, followed by samples with 1 hour incubation time and 0.5 hour infection time, then 0 hour incubation time and 0.5 hour infection time. The results also show that 0 hour incubation and 2 hour infection times produced the highest RLU, followed by samples with 1 hour incubation time and 0.5 hour infection time. Figure 2 shows that the 1 h infection has the lowest background signal.
[0246] Example 7. Further studies to test the effect of infection time on the sensitivity of the assay The experiment was set up as described in Example 2, except that after soaking the solid support with the bacterial turkey sample, the solid support was placed in medium and infection was performed immediately, i.e., there was no incubation time for the bacteria to grow on the solid support. Infection times varied from 30 minutes to 2 hours. Signal was detected as described above. Results for three samples are shown in Figure 7 and data are plotted in Figures 8A-8C. The results show that 2 hours of infection can increase the signal as shown in Samples 24 and 26, where 30 minutes showed no signal in the Hygiena, but 2 hours of infection did.
[0247] 9A-9C show a comparison between different devices, the GloMax device and the GloMax 20 / 20. The GloMax and GloMax 20 / 20 showed similar results.
[0248] Example 8. Testing of L. monocytogenes 19115 environmental sponge samples L. monocytogenes was inoculated onto a ceramic tile surface, dried, and left at room temperature for 18-24 hours. A sample sponge was used to wipe the ceramic tile, and the sponge was placed in a bag for enrichment at 35°C for 24 hours. The enriched sample was then sampled using the solid support as described in Example 2. 100 μl Listeria phage (concentration 1.2×10e8 PFU / ml) was used to infect a turkey culture of the bacteria at 30°C for 1 hour. Signal was detected using GloMax and Hygiena. The results are shown in Figure 10. The results show that the Hygiena portable can detect L. monocytogenes contaminated environmental samples.
[0249] Example 9. Different detection devices The experiment was set up as described in Example 2. Phage infection time was 1 hour at 37° C. Signals were read on GloMax, 3M portable luminometer ("3M"), and Hygiena. The results are shown in FIG. 11. It shows that 3M is more sensitive in detecting the signal.
[0250] Example 10. Preparation of CBC to detect microorganisms The gene fragment (NCBI accession YP_001468459) encoding the CBD of the endolysin was obtained by PCR on the genomic DNA of A511 phage using forward primer: tttagcgggcagtagcggagggTATGCTTACTTAAGCTCATG and reverse primer: tcgtcagtcagtcacgatgcTTATTTTTTGATAACTGCTCCTG. The sequence was then subcloned into pGEX4T-3 expression vector using Gibson Assembly according to the manufacturer's instructions to generate the GST-A511-CBD fusion protein. The map of the GST-A511-CBD expression plasmid is shown in Figure 16. The construct encoding the CBD of the endolysin was then transformed into E. coli BL21 strain (DE3) pLysS. The transformed cells were grown in liquid Luria-Bertani (LB) medium at 37°C to an optical density (OD) of 0.5-1.0. Expression of the CBC was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG). The cultures were incubated with shaking at 25°C for 5 hours.
[0251] Cells were harvested from the culture, lysed, and the GST-A511-CBD fusion protein was purified using GE Glutathione Sepharose 4B resin. Elution fractions from the resin were pooled, protein concentration was detected at 280 nm, aliquoted, and stored at -20°C.
[0252] The GST-A511-CBD protein was then biotinylated and used to bind to streptavidin magnetic beads (Dynabead M-280 Streptavidin beads).
[0253] Example 11. Detection of Microorganisms Using Beads as Solid Supports 1-2 ml of Listeria monocytogenes contaminated turkey sample, prepared as described in Example 1, is transferred to a tube. Beads coated with the CBD of the endolysin protein as described above are dipped into the sample. The beads are kept in the sample for a period of time to capture the maximum amount of bacteria. The beads are then returned to the device tube and medium is added. Either the solid support can be incubated in medium to expand the number of bacteria or phage can be added to initiate the infection cycle. After the infection cycle is complete, substrate is added and the sample is read in a handheld luminometer.
[0254] Illustrative Array SEQ ID NO: 1 Endolysin (YP_001468459) [ka] SEQ ID NO:2 CBD domain of endolysin [ka]
Claims
[Claim 1] The invention described in this specification.
Citation Information
Patent Citations
Methods and means for enrichment, isolation and detection of Listeria monocytogenes
JP2009505993A
Methods and means for enrichment, isolation, and detection of Gram-positive bacteria
JP2010512761A
Method for the enrichment of target cells by use of cbds
WO2004088321A1
